| Drug Sponsor |
Sponsor |
Medical Review |
Clinical Pharmacology Review |
Statistical Review |
BPCA or PREA or Both |
| Abametapir – Xeglyze |
HATCHTECH PTY LTD |
Medical (PDF – 4 MB)
Addendum (PDF – 78 KB)
CDTL (PDF – 3 MB)
Resubmission (PDF – 77 KB)
DD (PDF – 2 MB)
|
Clinical pharmacology (PDF – 6 MB) |
Statistical (PDF – 207 KB) |
PREA |
| Abacavir and Lamivudine – Epzicom |
ViiV Healthcare Company |
Medical (PDF – 3 MB) |
Clinical pharmacology (PDF – 158 KB) |
Statistical (PDF – 693 KB) |
PREA |
| Abacavir, Dolutegravir, and Lamivudine – Triumeq |
ViiV Healthcare Company |
Medical (PDF – 443 KB) |
Clinical pharmacology (PDF – 128 KB) |
None |
PREA |
Abacavir, Dolutegravir, and Lamivudine – Triumeq |
ViiV Healthcare Company c/o GlaxoSmithKline |
Medical (PDF – 389 KB)
CDTL (PDF – 798 KB)
|
Clinical pharmacology (PDF – 128 KB) |
None |
PREA |
| Abacavir, Dolutegravir, and Lamivudine – Triumeq PD |
ViiV Healthcare Company |
CDTL (PDF – 758 KB) |
Clinical pharmacology (PDF – 3 MB) |
None |
BOTH |
| Abacavir sulfate – Ziagen |
ViiV Healthcare Company |
Medical (PDF – 4.2 M B) |
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 5 MB) |
PREA |
| Abatacept – Orencia |
Bristol-Myers Squibb Company |
Medical (PDF – 259 KB)
Medical Addendum (PDF – 469 KB)
|
Clinical pharmacology (PDF – 2 MB)
Clinical pharmacology (PDF – 269 KB)
|
None |
BOTH |
| Abatacept – Orencia |
Bristol-Myers Squibb Company |
Medical (PDF – 4 MB) |
None |
None |
BPCA |
| AbobotulinumtoxinA – Dysport |
Ipsen Bipharm Limited |
CDTL Review (PDF – 2 MB)
Medical (PDF – 3 MB)
|
None |
Statistical (PDF – 2 MB) |
PREA |
| AbobotulinumtoxinA – Dysport |
Ipsen Bipharm Limited |
Medical (PDF – 1 MB) |
None |
Statistical (PDF – 857 KB) |
PREA |
Abrocitinib – Cibinqo |
Pfizer Inc. |
Medical (PDF – 10 MB) |
None |
None |
PREA |
| Abrocitinib – Cibinqo |
Pfizer Inc. |
Medical (PDF – 5 MB) |
None |
None |
PREA |
| Acetaminophen – Ofirmev |
MallInc.krodt, Inc. |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 5 MB) |
Statistical (PDF – 378 KB) |
BOTH |
| Acetylcysteine – Legubeti |
Galephar Pharmaceutical Research Inc. |
Unireview (PDF – 6 MB)
Unireview CR (PDF – 10 MB)
|
None |
None |
PREA |
| Acyclovir 5%, hydrocortisone 1% – Xerese |
Valeant International Bermuda |
Medical (PDF – 885 KB) |
None |
None |
PREA |
Adalimumab-adaz – Hyrimoz |
Sandoz Inc. |
Medical (PDF – 2 MB)
CDTL Review (PDF – 300 MB)
|
None |
None |
PREA |
|
Adalimumab-adaz – Hyrimoz
|
Sandoz Inc. |
CDTL Review (PDF – 342 KB)
|
None |
None |
PREA |
| Adalimumab-adaz – Hyrimoz |
Sandoz Inc. |
CDTL Review (PDF – 34 KB) |
None |
None |
PREA |
| Adalimumab-adbm – Cyltezo |
Boehringer Ingelheim |
Medical (PDF – 826 KB) |
None |
None |
PREA |
| Adalimumab-afzb – Abrilada |
Pfizer Inc. |
CDTL (PDF – 34 KB) |
None |
None |
PREA |
| Adalimumab-afzb – Abrilada |
Pfizer Inc. |
Medical (PDF – 1 MB) |
None |
None |
PREA |
| Adalimumab-afzb – Abrilada |
Pfizer Inc. |
CDTL (PDF – 34 KB) |
None |
None |
PREA |
| Adalimumab-aqvh – Yusimry |
Coherus BioSciences, Inc |
Medical (PDF – 5 MB) |
None |
None |
PREA |
| Adalimumab-aqvh – Yusimry |
Coherus BioSciences, Inc |
CDTL Review (PDF – 342 KB) |
Clinical pharmacology (PDF – 22 KB) |
None |
PREA |
| Adalimumab-atto – Amjevita |
Amgen Inc. |
CDTL Review (PDF – 4.3 MB)
Medical (PDF – 199K KB)
Medical (PDF – 336KB)
DD Summary Review (PDF – 3 MB)
|
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 416 KB)
Statistical (PDF – 363 KB)
Statistical (PDF – 717 KB)
|
PREA |
| Adalimumab-aaty – Yuflyma |
Celltrion, Inc. |
CDTL – DD (PDF – 356 KB) |
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
| Adalimumab-atto – Amjevita |
Amgen, Inc |
CDTL (PDF – 580 KB) |
None |
None |
PREA |
| Adalimumab-atto – Amjevita |
Amgen, Inc |
Medical (PDF – 532 KB) |
None |
None |
PREA |
Adalimumab-atto – Amjevita |
Amgen, Inc |
Medical (PDF – 532 KB) |
None |
None |
PREA |
| Adalimumab-atto – Amjevita |
Amgen Inc. |
Medical (PDF – 25 KB) |
None |
None |
PREA |
| Adalimumab-bwwd – Hadlima |
Samsung Bioepis Co., Ltd. |
Medical (PDF – 34 KB) |
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
| Adalimumab-bwwd – Hadlima |
Samsung Bioepis Co., Ltd. |
Medical (PDF – 34 KB) |
None |
None |
PREA |
| Adalimumab-fkjp – Hulio |
Mylan Pharmaceuticals Inc. |
Medical (PDF – 2 MB) |
None |
None |
PREA |
Adalimumab-fkjp – Hulio |
Mylan Pharmaceuticals Inc. |
Medical (PDF – 580 KB) |
None |
None |
PREA |
| Adalimumab-fkjp – Hulio |
Mylan Pharmaceuticals Inc. |
CDTL (PDF – 24 KB) |
None |
None |
RPEA |
| Adalimumab – Humira |
AbbVie,Inc. |
Medical (PDF – 2 MB) |
None |
None |
PREA |
| Adalimumab-aacf – Idacio |
Fresenius Kabi USA, LLC |
Medical (PDF – 20 MB) |
None |
None |
PREA |
| Adalimumab-aacf – Idacio |
Fresenius Kabi USA, LLC |
Medical (PDF – 20 MB) |
None |
None |
PREA |
| Adapalene and benzoyl peroxide – Epiduo |
Galderma Laboratories, LP |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF -124 KB) |
Statistical (PDF – 577 KB) |
PREA |
| Adapalene and benzoyl peroxide – Epiduo Forte |
Galderma Research and Development LLC |
Medical (PDF – 6.2 MB) |
Clinical pharmacology (PDF – 4 MB) |
Statistical (PDF – 2 MB) |
PREA |
|
Afatini – Gilotrif
|
Boehringer Ingelheim Pharmaceuticals, Inc. |
Medical (PDF – 5 MB) |
None |
None |
BPCA |
Aflibercept – Eylea |
Regeneron Pharmaceuticals, Inc. |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF – 5 MB) |
BPCA |
| Anidulafungin – Eraxis |
Vicuron Holdings LLC, a subsidiary of Pfizer Inc. |
Medical (PDF – 5 MB) |
None |
None |
PREA |
| Albuterol and Budesonide – Airsupra |
Bond Avillion 2 Development LP |
Medical (PDF – 12 MB) |
None |
None |
PREA |
| Albuterol sulfate – ProAir RespiClick |
Teva Pharmaceutical Products R. & D., Inc. |
Medical (PDF – 3 MB) |
Clinical pharmacology (PDF – 4 MB) |
Statistical (PDF – 2 MB) |
PREA |
| Albuterol sulfate – ProAir RespiClick |
Teva Branded Pharmaceutical Products R&D, Inc. |
Medical (PDF – 859 KB) |
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 1 MB) |
PREA |
| Alirocumab – Praluent |
Regeneron Pharmaceuticals, Inc |
Medical (PDF – 859 KB) |
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 1 MB) |
PREA |
| Aliskiren – Tekturna |
Noden Pharma DAC |
CDTL (PDF – 310 KB) |
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 442 KB) |
BOTH |
| Alogliptin – Nesina |
Takeda Pharmaceuticals U.S.A., Inc |
Medical (PDF – 6 MB) |
Clinical pharmacology (PDF – 937 KB) |
Statistical (PDF – 536 KB) |
PREA |
| Alogliptin and metformin – Kazano |
Takeda Pharmaceuticals U.S.A., Inc. |
Medical (PDF – 6 MB) |
Clinical pharmacology (PDF – 937 KB) |
Statistical (PDF – 536 KB) |
PREA |
|
Amlodipine benzoate – Katerzia
|
Silvergate Pharmaceuticals, Inc |
Medical (PDF – 46 KB) |
Clinical pharmacology (PDF – 337 KB) |
None |
PREA
|
| Amphetamine – Adzenys ER |
Neos Therapeutics, Inc. |
Medical (PDF – 1.9 MB) |
Clinical pharmacology (PDF – 4 KB) |
None |
PREA |
| Amphetamine Extended-Release Orally Disintegrating Tablets – Adzenys XR-ODT |
Neos Therapeutics, Inc. |
Medical (PDF – 470 KB) |
Clinical pharmacology (PDF -3 MB) |
None |
PREA |
| Amphetamine – Dyanavel XR |
Tris Pharma |
Medical (PDF – 1.8 MB) |
Clinical pharmacology (PDF – 5 MB) |
Statistical (PDF – 767 KB) |
PREA |
| Amphetamine – Dyanavel XR |
Tris Pharma |
Medical (PDF – 848 KB)
CDTL Review (PDF – 1 MB)
|
None |
None |
PREA |
|
Amphetamine sulfate – Evekeo
|
Arbor Pharmaceuticals, LLC |
Medical (PDF – 1 MB)
Medical (PDF – 155 KB)
|
Clinical pharmacology (PDF – 9 KB)
Clinical pharmacology memo (PDF – 9 KB)
|
Statistical (PDF – 532 KB) |
PREA |
| Apremilast – Otezla |
Amgen, Inc |
Medical (PDF – 7 MB) |
None |
None |
PREA |
| Aprepitant – Emend |
Merck Sharp & Dohme Corp. |
Medical (PDF – 6 MB)
Medical Addendum (PDF -1 MB)
Medical DD memo (PDF – 3 MB)
|
Clinical pharmacology (PDF – 5 MB)
Clinical pharmacology addendum (PDF – 424 KB)
|
Statistical (PDF – 1 MB) |
PREA |
| Aprepitant – Emend |
Merck Sharp & Dohme Corp. |
Medical (PDF – 553 KB) |
Clinical pharmacology (PDF – 5 MB)
Addendum (PDF -105 KB)
|
Statistical (PDF – 1 MB) |
PREA |
| Aripiprazole – Abilify |
Otsuka |
Medical (PDF – 2.4MB) |
None |
Statistical (PDF – 409 KB) |
PREA |
| Asenapine – Saphris |
Forest Laboratories, Inc. |
Medical (PDF – 5 MB)
Medical (PDF – 4 MB)
|
Clinical pharmacology (PDF – 4 MB) |
Statistical (PDF – 3 MB) |
BOTH |
| Asparaginase erwinia chrysanthemi (recombinant)- rywn – Rylaze |
Jazz Pharmaceuticals Ireland Limited |
Medical (PDF – 4 MB) |
None |
None |
PREA |
| Atazanavir and cobicistat – Evotaz |
Bristol-Myers Squibb Company |
CDTL (PDF – 402 KB) |
Clinical pharmacology (PDF -1 MB) |
None |
PREA |
| Atazanavir – Reyataz |
Bristol-Myers Squibb Company |
Medical (PDF – 14 MB) |
Clinical pharmacology (PDF -1 MB) |
Statistical (PDF – 2 MB) |
BOTH |
| Atazanavir – Reyataz |
Bristol-Myers Squibb Company |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF – 4 MB) |
BOTH |
|
Atezolizumab – TECENTRIQ
|
Genentech, Inc. |
Medical (PDF – 1 MB) |
None |
None |
BPCA |
|
Atezolizumab – Tecentriq
|
Genentech, Inc. |
Medical (PDF – 3 MB) |
None |
None |
BPCA |
| Atorvastatin calcium – Atorvaliq |
CMP Development LLC |
Medical (PDF – 3 MB) |
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
|
Atropine-pralidoxime – DueDote
|
Meridian Medical Technologies, Inc. |
CDTL (PDF – 402 KB)
Medical (PDF – 886 KB)
|
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
| Atropine Sulfate – Isopto Atropine 1% |
Alcon Research, Ltd. |
Medical (PDF – 663KB) |
Clinical pharmacology (PDF – 480KB) |
Statistical (PDF – 230KB) |
PREA |
| Atropine Sulfate Ophthalmic Solution |
Akorn, Inc. |
Medical (PDF – 1.2 MB) |
Clinical pharmacology (PDF – 1MB) |
Statistical (PDF – 287KB) |
PREA |
| Azelastine hydrochloride – Astepro |
Meda Pharmaceuticals |
Clinical (PDF -1 .4MB) |
None |
Statistical (PDF -473 KB |
PREA |
| Azelastine hydrochloride – Astepro |
Meda Pharmaceuticals Inc. |
Medical (PDF – 2MB) |
None |
None |
BOTH |
| Azelastine hydrochloride and Fluticasone propionate – Dymista |
Meda Pharmaceuticals, Inc. |
Medical (PDF – 2.9MB) |
None |
Statistical (PDF -2.1MB) |
BOTH |
| Baclofen – Fleqsuvy |
Azurity Pharmaceuticals, Inc. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 367 KB) |
None |
PREA |
| Baclofen – Lyvispah |
Saol Therapeutics Research Limited |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 448 KB) |
None |
PREA |
|
Baloxavir marboxil – Xofluza
|
Shionogi, Incorporated
|
CDTL (PDF – 869 KB)
Medical (PDF – 414 KB)
|
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 2 MB) |
PREA |
| Baloxavir marboxil – Xofluza |
Genentech, Incorporated |
CDTL (PDF – 853 KB)
Medical (PDF – 6 MB KB)
|
Clinical pharmacology (PDF – 420 KB) |
None |
PREA |
| Baloxavir marboxil – Xofluza |
Genentech, Incorporated |
Medical (PDF – 11 MB) |
None |
None |
PREA |
| Barium sulfate – E-Z-HD |
Bracco Diagnostics Inc. |
Medical (PDF – 2.4MB) |
Clinical pharmacology (PDF -642KB) |
Statistical (PDF -988KB) |
PREA |
| Barium sulfate – READI-CAT 2 & READI-CAT 2 SMOOTHIE |
Bracco Diagnostics |
Medical (PDF – 2.4MB) |
Clinical pharmacology (PDF – 702 KB) |
Statistical (PDF -1 MB) |
PREA |
| Barium sulfate – Varibar Pudding |
Bracco Diagnostics, Inc. |
Medical (PDF – 1MB) |
None |
None |
PREA |
| Barium sulfate – Liquid E-Z-Paque |
Bracco Diagnostics, Inc. |
DD Summary Review (PDF – 233 KB) |
None |
None |
PREA |
| Beclomethasone dipropionate – Qnasl |
Teva Branded Pharmaceutical Products R&D, Inc. |
Medical (PDF – 4 MB) |
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF -959 KB) |
PREA |
|
Belumosudil – Rezurock
|
Kadmon Pharmaceuticals, LLC |
Medical (PDF – 7MB) |
Non |
None |
PREA |
| Belimumab – Benlysta |
Human Genome Sciences |
Medical (PDF – 6 MB) |
None |
None |
PREA |
| Belimumab – Benlysta |
GlaxoSmithKline LLC |
Medical (PDF – 7 MB) |
None |
None |
PREA |
| Benralizumab – Fasenra |
AstraZeneca AB |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 7 MB) |
Statistical (PDF – 2 MB) |
PREA |
| Benralizumab – Fasenra |
AstraZeneca AB c/o AstraZeneca Pharmaceuticals LP |
Medical (PDF – 7 MB)
Unireview (PDF – 11 KB)
|
None |
None |
PREA |
| Berdazimer – Zelsuvmi |
LNHC, Inc. |
Medical (PDF – 12 MB) |
None |
None |
PREA |
| Bezlotoxumab – Zinplava |
Merck Sharp & Dohme Corp. |
Medical (PDF – 2 MB) |
None |
None |
BOTH |
| Bictegravir, emtricitabine, and tenofovir alafenamide – Biktarvy |
Gilead Sciences, Inc. |
CDTL (PDF – 157 KB)
CDTL 1 (PDF – 2 MB)
|
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
| Bictegravir, emtricitabine, and tenofovir alafenamide – Biktarvy |
Gilead Sciences, Inc. |
CDTL (PDF – 2 MB) |
Clinical pharmacology (PDF – 4 MB) |
None |
PREA |
| Bimatoprost ophthalmic solution, 0.03% – Latisse |
Allergan, Inc. |
DD Summary Review (PDF – 966KB)
CDTL Review (PDF – 3 MB)
Medical (PDF – 2 MB)
|
None |
Statistical (PDF -946KB)
Statistical Addendum (PDF – 127KB)
|
PREA |
|
Blinatumomab – Blincyto
|
Amgen, Inc. |
Medical (PDF – 3 MB) |
Clinical pharmacology (PDF -1 MB) |
Statistical (PDF -374 KB) |
BPCA |
| Blinatumomab – Blincyto |
Amgen, Inc. |
Medical (PDF – 9 MB) |
None
|
None |
BPCA |
| Bortezomib – Velcade |
Millennium Pharmaceuticals, Inc. |
Medical (PDF – 4 MB) |
Clinical pharmacology (PDF -1 MB) |
Statistical (PDF – 374 KB) |
BPCA |
| Bosutinib – BOSULIF |
PF Prism C.V |
Medical (PDF – 10 MB) |
None |
None |
BPCA |
| Budesonide – Entocort EC |
Elan Pharma International |
Medical (PDF – 3 MB) |
Clinical pharmacology (PDF – 3 MB) |
Clinical pharmacology (PDF – 3 MB) |
PREA |
| Brentuximab vedotin – Adcetris |
Seagen Inc. |
Medical (PDF – 1 MB) |
None |
None |
BPCA |
|
Brexanolone – Zulresso
|
Sage Therapeutics, Inc. |
Medical (PDF – 1 MB) |
None |
None |
PREA |
Brexpiprazole – Rexulti |
Otsuka Pharmaceutical Company, Ltd. |
Medical (PDF – 4 MB) |
None |
None |
PREA |
| Brimonidine tartrate – Lumify |
Bausch + Lomb |
CDTL Review (PDF – 3 MB)
Medical (PDF – 556 KB)
|
Clinical pharmacology (PDF – 51 KB) |
Statistical (PDF – 219 KB) |
PREA |
| Brivaracetam – Briviact |
UCB, Inc. |
CDTL Review (PDF – 297 KB)
Medical (PDF – 1 MB)
|
Clinical pharmacology (PDF – 2 MB) |
None |
PREA
|
| Brivaracetam – Briviact |
UCB, Inc. |
Medical (PDF – 74 KB) |
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
| Budesonide/formoterol fumarate dehydrate – Symbicort |
AstraZeneca Pharmaceuticals, LP |
Medical (PDF – 3.4 MB) |
Clinical pharmacology (PDF – 1.2 MB) |
Statistical (PDF – 2.5 MB) |
BOTH |
| Bupivacaine – Exparel |
Pacira Pharmaceuticals, Inc. |
Medical (PDF – 6 MB) |
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
| Buprenorphine – Butrans |
Purdue Pharma L.P. |
Medical (PDF – 4.1 MB) |
Clinical pharmacology (PDF – 1.5 MB) |
None |
PREA |
| Cabazitaxel – Jevtana |
Sanofi-Aventis U.S., L.L.C. |
Medical (PDF – 1.5 MB) |
Clinical pharmacology (PDF – 1.2 MB) |
None |
BPCA |
|
Cabotegravir – Apretude
|
ViiV Healthcare Company |
Medical (PDF – 8 MB) |
None |
None |
PREA |
Cabotegravir-rilpivirine – Cabenuva |
ViiV Healthcare Company |
Medical (PDF – 35 KB) |
Clinical pharmacology (PDF – 1 MB)
Clinical pharmacology Addendum (PDF – 229 KB)
|
None |
PREA |
| Cabotegravir – Vocabria |
ViiV Healthcare Company |
CDTL (PDF – 1 MB)
Medical (PDF – 525 KB)
|
Clinical pharmacology (PDF – 2 MB)
Addendum (PDF – 115 KB)
|
None |
PREA |
| Calcipotriene – SORILUX Foam |
Mayne Pharma LLC |
Medical (PDF – 525 KB) |
None |
None |
PREA |
| Calcipotriene – SORILUX |
Mayne Pharma LLC |
Medical (PDF – 525 KB) |
Clinical pharmacology (PDF – 1.2 MB) |
None |
PREA |
| Calcipotriene and Betamethasone dipropionate – Taclonex |
LEO Pharma A/S |
Medical (PDF -5.6MB) |
Clinical pharmacology (PDF -2.4MB) |
Statistical (PDF -564 KB) |
PREA |
| Calcipotriene and Betamethasone dipropionate – Taclonex |
LEO Pharma A/S c/o LEO Pharma, Inc. |
Medical (PDF – 3.7MB) |
Clinical pharmacology (PDF -2.7MB) |
None |
PREA |
| Calcipotriene and Betamethasone dipropionate – Taclonex |
LEO Pharma A/S |
Medical (PDF – 775 KB) |
Clinical pharmacology (PDF – 528 KB) |
None |
PREA |
| Calcipotriene and betamethasone – Enstilar |
LEO Pharma A/S |
Medical (PDF – 775 KB) |
N |
None |
BOTH |
| Calcium Gluconate injection – Calcium Gluconate Injection |
Fresenius Kabi USA, LLC |
Medical (PDF – 4 MB)
Medical CTDL (PDF – 1.5 MB)
|
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
Calcitriol – Vectical |
Galderma Laboratories, L.P. |
Medical (PDF – 3 MB) |
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
| Cantharidin – Ycanth |
Verrica Pharmaceuticals Inc. |
Medical (PDF – 3 MB) |
None |
None |
PREA |
| Capecitabine – Xeloda |
Hoffmann-La Roche, Inc. |
Medical (PDF – 4MB) |
Clinical pharmacology (PDF – 1MB) |
Statistical (PDF -610 KB) |
BPCA |
| Carbinoxamine maleate – Karbinal ER |
Tris Pharma, Inc. |
Medical (PDF – 1.4MB) |
Clinical pharmacology (PDF – 500 KB) |
None |
PREA |
| Cefazolin sodium and dextrose solution – Cefazolin for Injection USP and Dextrose Injection USP in the Duplex® Container |
B. Braun Medical Inc. |
Medical (PDF – 1 MB) |
None |
None |
PREA |
| Ceftaroline fosamil – Teflaro |
Cerexa, Inc., A Subsidiary of Forest Laboratories, LLC |
Medical (PDF – 11 MB)
Medical CTDL (PDF – 2 MB)
|
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF -1 MB) |
PREA |
| Ceftaroline fosamil – Teflaro |
Allergan Sales, LLC |
Medical (PDF – 5 MB) |
None |
None |
PREA |
| Ceftazidime and Avibactam – Avycaz |
Allergan Sales, LLC |
Medical (PDF – 5 MB) |
None |
None |
PREA |
| Ceftazidime and avibactam – Avycaz |
Allergan Sales, LLC |
Medical (PDF – 4 MB) |
None |
None |
PREA |
| Ceftazidime and avibactam – Avyca |
AbbVie, Inc. |
Medical (PDF – 4 MB) |
None |
None |
PREA |
| Ceftobiprole medocaril sodium for injection – Zevtera |
Basilea Pharmaceutica International, Ltd., Allschwil |
Medical (PDF – 4 MB) |
None |
None |
PREA |
| Ceftolozane and tazobactam – Zerbaxa |
Cubist Pharmaceuticals, LLC |
Medical (PDF – 8 MB) |
None |
None |
PREA |
| Certolizumab pegol – Cimzia |
UCB, Inc |
Medical (PDF – 4 MB) |
None |
None |
PREA |
| Cetirizine ophthalmic solution – Zerviate |
Nicox Ophthalmics, Inc. |
Medical Resubmission (PDF – 231 KB)
Medical (PDF – 5 MB)
|
Clinical pharmacology (PDF – 279 KB) |
Statistical (PDF – 580 KB) |
BOTH |
| Cetirizine hydrochloride – Quzyttir |
JDP Therapeutics Inc |
Medical (PDF – 2 MB) |
None |
None |
PREA |
| Ciclesonide – Zetonna |
Takeda GmbH |
Medical (PDF – 5 MB)
|
Clinical pharmacology (PDF -1 MB) |
Statistical (PDF -674 KB) |
PREA |
| Cinacalcet hydrochloride – Sensipar |
|
CDTL (PDF – 2.2 MB)
Medical (PDF – 4.1 MB)
|
Clinical pharmacology (PDF – 5.6 MB) |
Statistical (PDF – 957 KB) |
BOTH |
| Ciprofloxacin 0.3% and Fluocinolone acetonide 0.025% – Otovel Otic Solution |
Laboratorios SALVAT, S.A. |
Medical (PDF – 4MB) |
Clinical pharmacology (PDF -632 KB) |
Statistical (PDF -2MB) |
PREA |
| Ciprofloxacin otic suspension – Otiprio |
Otonomy, Inc. |
Medical (PDF – 233 KB) |
Clinical pharmacology (PDF – 79 KB) |
Statistical (PDF – 213 MB |
PREA |
| 6% Ciprofloxacin Otic Suspension – Otiprio |
Otonomy, Inc. |
Medical (PDF – 2.3MB) |
Clinical pharmacology (PDF – 97 KB) |
Statistical (PDF -896 KB)
Addendum (PDF -157 KB
|
PREA |
| Ciprofloxacin ophthalmic solution – Ciloxan |
Novartis Pharmaceuticals Corporation |
Medical (PDF – 110 KB)
Medical (PDF – 173 KB)
|
None |
None |
BPCA |
|
Clascoterone – Winlevi
|
Cassiopea SpA |
Medical (PDF – 3 MB) |
None |
None |
PREA |
|
Clindamycin phosphate, adapalene, and benzoyl peroxid – Cabtreo
|
Bausch Health US, LLC |
Medical (PDF – 4 MB) |
None |
None |
PREA |
| Clindamycin phosphate – Xaciato |
Daré Bioscience Inc. |
Medical (PDF – 3 MB) |
None |
None |
PREA |
| Clonidine – Kapvay |
Concordia Pharms Inc. |
Medical (PDF – 3 MB) |
None |
Statistical (PDF -2MB) |
PREA |
| Cobicistat – Tybost |
Gilead Sciences, Inc. |
CDTL (PDF – 1 MB) |
Clinical pharmacology (PDF – 1 MB) |
None |
BOTH |
Cobimetinib – Cotellic |
Genentech, Inc. |
Medical (PDF – 27 KB) |
Clinical pharmacology (PDF – 543 KB) |
None |
BPCA |
| Colesevelam HCl – Welchol |
Daiichi Sankyo Inc. |
CDTL (PDF – 2 MB)
Medical (PDF – 12MB)
|
Clinical pharmacology (PDF – 7 MB) |
None |
PREA |
| Colesevelam HCl – Welchol |
Daiichi Sankyo Inc. |
Medical (PDF – 3 MB) |
None |
Statistical (PDF – 308 KB) |
PREA |
| Crisaborole Ointment, 2% – Eucrisa |
Anacor Pharmaceuticals Inc. |
CDTL Review (PDF – 2MB)
Medical (PDF – 12MB)
|
Clinical pharmacology (PDF – 7MB) |
Statistical (PDF – 1MB) |
PREA |
| Crisaborole – Eucrisa |
Anacor Pharmaceuticals, LLC. |
Medical (PDF – 2 MB) |
None |
None |
PREA |
| Crisaborole – Eucrisa |
Pfizer |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 1 MB) |
None |
BPCA |
| Cysteamine bitartrate – Procysbi |
Raptor Pharmaceuticals, Inc. |
Medical (PDF -12MB) |
Clinical pharmacology (PDF – 2 MB)
Clinical pharmacology addendum (PDF – 420 KB)
|
None |
BPCA |
| Cysteamine bitartrate – Procysbi |
Horizon Pharma USA, Inc. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF – 1 MB) |
BPCA |
| Cysteamine hydrochloriden – CYSTADROPS |
Recordati Rare Diseases Inc. |
Medical (PDF – 294 KB) |
None |
None |
PREA |
Dabigatran etexilate – Pradaxa |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Medical (PDF – 2 MB)
Medical (PDF – 700 KB)
|
Clinical pharmacology (PDF – 5 MB) |
None |
BOTH |
| Dabrafenib – Tafinlar |
Novartis Pharmaceuticals Corporation |
Medical (PDF – 18 MB) |
None |
None |
PREA |
| Dabrafenib – Tafinlar |
Novartis Pharmaceuticals Corporation |
Medical (PDF – 10 MB)
CDTL (PDF – 1 MB)
|
Clinical pharmacology (PDF – 579 KB) |
None |
BPCA |
|
Dalbavancin hydrochloride – Dalvance
|
Allergan Sales, LLC |
Medical (PDF – 2 MB) |
None |
None |
PREA |
| Dalteparin sodium – Fragmin |
Pharmacia & Upjohn, a subsidiary of Pfizer Inc. |
Medical (PDF – 3.5 MB) |
None |
None |
PREA |
| Darunavir, cobicistat, emtricitabine, and tenofovir alafenamide – Symtuza |
Jannsen |
Medical (PDF – 3.5 MB) |
Clinical pharmacology (PDF – 1.2MB) |
None |
PREA |
| Dapsone – Aczone |
Allergan, Inc. |
Medical (PDF – 3.5 MB) |
Clinical pharmacology (PDF – 2.6 MB) |
Statistical (PDF -1.3 MB) |
PREA |
| Dapsone – Aczone |
Almirall, LLC |
Medical (PDF – 3.5 MB) |
Clinical pharmacology (PDF – 2.6 MB) |
None |
PREA |
| Daptomycin – Cubicin |
Cubist Pharmaceuticals, LLC c/o Merck Sharp & Dohme Corp. |
Medical (PDF – 505 KB) |
Clinical pharmacology (PDF – 1.8 MB)
|
Statistical (PDF -1.9 KB)
Statistical Addendum (PDF – 96 KB)
|
PREA |
| Daptomycin – Cubicin |
Cubist Pharmaceuticals, LLC c/o Merck Sharp & Dohme Corp. |
Medical (PDF – 389 KB) |
Clinical pharmacology (PDF – 991 KB)
Clinical pharmacology Addendum (PDF – 80 KB)
|
Statistical (PDF – 374 KB)
|
PREA |
Daptomycin – Dapzura RT |
Baxter Healthcare Corporation |
Medical (PDF – 2 MB) |
None |
None |
PREA |
| Darbepoetin alfa – Aranesp |
Amgen Inc. |
Medical (PDF – 2 MB) |
None |
Statistical (PDF -280KB) |
BPCA |
| Darunavir and Cobicistat – Prezcobix |
Janssen Products, LP |
Medical (PDF – 147 KB) |
Clinical pharmacology (PDF – 20 KB) |
None |
PREA |
| Darunavir – Prezista |
Janssen Products, L.P. |
Medical (PDF -1MB) |
Clinical pharmacology (PDF -1MB) |
None |
PREA |
| Darunavir – Prezista |
Janssen Products, L.P. |
None |
Clinical pharmacology (PDF -352KB) |
None |
PREA |
| Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide – Symtuza |
Janssen Products, L.P. |
Multi-disciplinary review (PDF – 8 MB) |
None |
None |
PREA |
|
Dasatinib – Sprycel
|
Bristol-Myers Squibb Company
|
CDTL Review (PDF – 1 MB)
Medical (PDF- 8 MB)
|
Clinical pharmacology (PDF – 531 KB)
|
Statistical (PDF – 19 KB) |
BPCA |
| Dasiglucagon – Zegalogue |
Zealand Pharma A/S |
Medical (PDF – 5MB) |
Clinical pharmacology (PDF – 33KB)
Clinical pharmacology Addendum (PDF – 38KB)
|
Statistical (PDF – 2MB) |
PREA |
| Daunorubicin and cytarabine (liposome injection) – Vyxeos |
Jazz Pharmaceuticals |
Multidisciplinary (PDF – 5 MB) |
None |
None |
BPCA |
| Decitabine – Dacogen |
Eisai Inc. |
Medical (PDF -2 MB) |
Clinical pharmacology (PDF -1MB) |
None |
BPCA |
| Deferasirox – Exjade |
Novartis Pharmaceuticals Corporation |
Medical (PDF – 9 MB) |
Clinical pharmacology (PDF – 1.5MB) |
Statistical (PDF – 2MB) |
BPCA |
| Deferasirox – Exjade |
Novartis Pharmaceuticals Corporation |
CDTL Review (PDF – 795 KB)
Medical (PDF – 843 KB)
|
None |
None |
BPCA |
| Deferasirox – Jadenu |
Novartis Pharmaceuticals Corporation |
CDTL Review (PDF – 2MB)
Medical (PDF – 1 MB)
|
Clinical pharmacology (PDF – 1MB) |
None |
BPCA |
| Desoximetasone – Topicort |
Taro Pharmaceuticals U.S.A., Inc. |
Medical (PDF – 221 KB) |
Clinical pharmacology (PDF – 302 KB) |
None |
PREA |
| Desvenlafaxine – Pristiq |
Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. |
Medical (PDF – 103 KB)
Medical (PDF – 622 KB)
|
Clinical pharmacology (PDF – 1.5 MB) |
Statistical (PDF – 1.5 MB) |
PREA |
|
Deutetrabenazine – Austedo
|
Teva Branded Pharmaceutical Products R&D, Inc. |
Medical (PDF – 622 KB) |
None |
None |
BPCA |
| Dexlansoprazole – Dexilant |
Takeda Pharmaceuticals USA Inc. |
CDTL Review (PDF-661 KB)
Medical (PDF-5 MB)
|
Clinical pharmacology (PDF-1MB) |
Statistical (PDF-50KB) |
PREA |
| Dexmedtomidine hydrochloride – Precedex |
Hospira |
Medical (PDF -5MB) |
Clinical pharmacology (PDF -3.8MB) |
Statistical (PDF -1MB) |
BPCA |
| Dexmedetomidine – Precedex |
Hospira, Inc. |
CDTL Review (PDF – 3 MB) |
Clinical pharmacology (PDF -3.8MB) |
Statistical (PDF – 1MB) |
PREA |
| Dextroamphetamine – Xelstrym |
Noven Pharmaceuticals, Inc. |
Medical (PDF – 1 MB) |
None |
None |
PREA |
|
Diclofenac epolamine topical system 1.3% – Flector
|
IBSA Institut Biochimique SA
|
Medical (PDF – 1 MB)
|
None |
None |
PREA |
Diclofenac potassium – Zipsor |
Assertio Therapeutics, Inc. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 453 KB) |
None |
PREA |
| Difluprednate ophthalmic emulsion – Durezol |
Alcon Pharmaceuticals Ltd. c/o Alcon Research Ltd |
Medical (PDF -748 KB) |
Clinical pharmacology (PDF – 40KB) |
Statistical (PDF – 479KB) |
BPCA |
| Dolutegravir and lamivudine – Dovato |
ViiV Healthcare Company |
Medical (PDF – 2 MB) |
None |
None |
PREA |
| Dolutegravir – Tivicay |
ViiV Healthcare |
Medical (PDF – 8MB) |
Clinical pharmacology (PDF -11 MB) |
Statistical (PDF -4MB) |
PREA |
| Dolutegravir – Tivicay |
ViiV Healthcare |
Medical (PDF – 2 MB)
CDTL Review (PDF – 932 KB)
|
Clinical pharmacology (PDF -2.2MB) |
None |
PREA |
| Dolutegravir – Tivicay PD |
ViiV Healthcare |
Medical (PDF – 241KB) |
Clinical pharmacology (PDF -89KB) |
None |
PREA |
| Doravirine/lamivudine/tenofovir disoproxil fumarate – Delstrigo |
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. |
CDTL Review (PDF – 962 KB) |
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
| Doxycycline hyclate delayed-release – Doryx |
Mayne Pharma International, Pty, Ltd. c/o Warner Chilcott US, LLC |
Medical (PDF – 241 KB) |
Clinical pharmacology (PDF – 89 KB) |
Statistical (PDF – 131 KB) |
PREA |
| Doxycycline hyclate – LymePak |
Chartwell Pharma NDA B2 Holdings, LLC |
Medical (PDF – 1 MB) |
None |
None |
PREA |
Drospirenone and estetrol tablets – Nextstellis |
Mayne Pharma LLC |
Medical (PDF – 3 MB) |
None |
None |
PREA |
| Drospirenone – Slynd |
Exeltis USA, Inc |
Medical (PDF – 1 MB) |
None |
None |
PREA |
| Dulaglutide – Trulicity |
Eli Lilly and Company |
CDTL (PDF – 1 MB) |
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 2 MB) |
BOTH |
| Duloxetine – Cymbalta |
Eli Lilly and Company, Inc. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF -197KB) |
Statistical (PDF – 3 MB) |
PREA |
| Duloxetine – Cymbalta |
Eli Lily and Company, Inc. |
Medical (PDF – 2 MB) |
None |
None |
PREA |
Duloxetine delayed-release capsules – Drizalma Sprinkle |
Sun Pharma Global FZE |
Medical (PDF – 2 MB) |
None |
None |
PREA |
| Duloxetine hydrochloride – Cymbalta |
Eli Lilly and Company |
Medical (PDF – 8 MB) |
Clinical pharmacology (PDF – 959 KB) |
Statistical (PDF -665 KB) |
BPCA |
| Dupilumab – Dupixent |
Regeneron Pharmaceuticals, Inc. |
Medical (PDF – 8 MB) |
None |
None |
PREA |
| Dupilumab – Dupixent |
Regeneron Pharmaceuticals, Inc. |
Medical (PDF – 8 MB) |
None |
None |
PREA |
| Dupilumab – Dupixent |
Regeneron Pharmaceuticals, Inc. |
Medical (PDF – 5 MB) |
None |
None |
PREA |
| Dupilumab – Dupixent |
Regeneron Pharmaceuticals, Inc. |
Medical (PDF – 5 MB) |
None |
None |
PREA |
| Dupilumab – Dupixent |
Regeneron Pharmaceuticals, Inc. |
Medical (PDF – 5 MB) |
None |
None |
PREA |
| Econazole nitrate – Ecoza |
AmDerma Pharmaceuticals, LLC |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 422KB) |
PREA |
| Edoxaban – Savaysa |
Daiichi Sankyo, Inc. |
CDTL (PDF – 4 MB)
Medical (PDF – 4 MB)
|
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
| Efavirenz, lamivudine, tenofovir – Symfi Lo |
Mylan Pharmaceuticals, Inc. |
Medical (PDF – 129 KB) |
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
| Efavirenz, lamivudine, tenofovir Disoproxil Fumarate – Symfi |
Mylan Pharmaceuticals, Inc. |
Medical (541 – KB) |
None |
None |
PREA |
| Efavirenz, Lamivudine and Tenofovir disoproxil fumarate |
Aurobindo Pharma Limited, India |
DD Review (PDF – 65 KB) |
Clinical pharmacology (PDF – 788 KB) |
None |
PREA |
|
Efavirenz, lamivudine, tenofovir disoproxil fumarate
|
Macleods Pharmaceuticals Limited, India |
Medical (PDF – 1.9MB) |
Clinical pharmacology (PDF – 788 KB) |
None |
PREA |
| Efavirenz – Sustiva |
Bristol-Myers Squibb Company |
Medical (PDF -1.9MB) |
Clinical pharmacology (PDF -9.3MB) |
None |
BOTH |
| Efinaconazole – Jublia |
Bausch Health Americas, Inc.
|
Medical (PDF – 538 KB) |
None |
None |
PREA |
|
Elbasvir and grazoprevir – Zepatier
|
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
| Eltrombopag – Alvaiz |
Teva Pharmaceuticals Inc. |
CDTL (PDF – 2 MB)
Medical (PDF – 583 MB)
|
Clinical pharmacology (PDF – 975 MB) |
None |
PREA |
| Eltrombopag – Promacta |
Novartis Pharmaceuticals Corporation |
Medical (PDF – 4 MB) |
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF -1MB) |
BPCA |
| Eltrombopag – Promacta |
Novartis Pharmaceuticals Corporation |
Medical (PDF – 58 KB) |
None |
None |
BPCA |
| Eltrombopag – Promacta |
Novartis Pharmaceuticals Corporation |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 97 KB) |
BPCA |
| Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir alafenamide – Genvoya |
Gilead Sciences, Inc. |
Medical (PDF -13.4MB) |
Clinical pharmacology (PDF -24.2MB) |
Statistical (PDF -2.2MB) |
PREA |
| Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir alafenamide – Genvoya |
Gilead Sciences, Inc. |
Medical (PDF – 642 KB) |
Clinical pharmacology (PDF – 242 KB) |
None |
BOTH |
|
Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir alafenamide – Genvoya
|
Gilead Sciences, Inc. |
CDTL (PDF – 3 MB) |
Clinical pharmacology (PDF – 9 MB) |
None |
BOTH |
| Elvitegravir, Cobicistat, Emtricitabine/Tenofovir Disoproxil Fumarate – Stribild |
Gilead Sciences, Inc. |
CTDL Review (PDF -359KB) |
Clinical pharmacology (PDF – 462KB) |
None |
PREA |
| Empagliflozin – Jardiance |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Medical – CDTL (PDF – 7 MB) |
Clinical pharmacology (PDF – 4 MB) |
Statistical (PDF – 2 MB) |
BPCA |
| Empagliflozin and Metformin – Synjardy |
Boehringer Ingelheim Pharmaceuticals, Inc. |
CDTL (PDF – 7 MB) |
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 3 MB) |
BPCA |
| Empagliflozin and Metformin – Synjardy XR |
Boehringer Ingelheim Pharmaceuticals, Inc. |
CDTL (PDF – 7 MB) |
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 3 MB) |
BPCA |
| Emtricitabine, Rilpivirine, and Tenofovir alafenamide – Odefsey |
Gilead Sciences, Inc. |
Medical (PDF – 310KB)
CTDL Review (PDF – 578KB)
|
Clinical pharmacology (PDF – 5MB)
Clinical pharmacology addendum (PDF – 297 KB)
|
None |
PREA |
| Emtricitabine, Rilpivirine, and Tenofovir alafenamide – Descovy |
Gilead Sciences, Inc. |
Medical (PDF – 1 MB)
Addendum (PDF – 572KB)
|
Clinical pharmacology (PDF -8 MB) |
Statistical (PDF -2 MB) |
PREA |
| Emtricitabine, Rilpivirine, and Tenofovir alafenamide – Descovy |
Gilead Sciences, Inc. |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 8 MB) |
Statistical (PDF – 2 MB) |
PREA |
| Emtricitabine and tenofovir alafenamide – Descovy |
Gilead Sciences, Inc. |
Medical (PDF – 642 KB) |
Clinical pharmacology (PDF -145 KB) |
None |
PREA |
| Emtricitabine and tenofovir alafenamide – Descovy |
Gilead Sciences, Inc. |
CDTL Review (PDF – 2 MB) |
None |
None |
PREA |
| Emtricitabine, Rilpivirine, and Tenofovir isoproxil fumarate – Complera |
Gilead Sciences, Inc. |
Medical (PDF – 1MB) |
Clinical pharmacology (PDF -145 KB) |
None |
PREA |
| Emtricitabine and Tenofovir disoproxil fumarate – Truvada |
Gilead Sciences, Inc. |
Medical (PDF – 501KB) |
Clinical pharmacology (PDF -189KB) |
None |
PREA |
| Entecavir – Baraclude |
Bristol-Myers Squibb Company |
Medical (PDF – 3 MB) |
Clinical pharmacology (PDF – 3MB) |
Statistical (PDF -660 KB) |
BOTH |
| Entrectinib – Rozlytrek |
Genentech |
Medical (PDF – 23 MB) |
None |
None |
BPCA |
| Entrectinib – Rozlytrek |
Genentech, Inc. |
Medical (PDF – 14 MB) |
None |
None |
BPCA |
| Erlotinib – Tarceva |
OSI Pharmaceuticals, LLC |
Medical (PDF – 6 MB) |
Clinical pharmacology (PDF -2 MB) |
None |
BPCA |
| Eribulin mesylate – Halaven |
Eisai Inc. |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 2 MB) |
None |
BPCA |
| Epinephrine – Auvi-Q |
Kaleo, Inc. |
Medical (PDF – 2 MB) |
None |
None |
PREA |
| Epinephrine – Primatene Mist |
Armstrong Pharmaceuticals, Inc. |
CDTL Review (PDF – 2 MB)
Medical (PDF – 4 MB)
|
None |
Statistical (PDF – 660 KB) |
PREA |
| Escitalopram oxalate – Lexapro |
Forest Laboratories, Inc. |
Medical (PDF – 218 KB) |
None |
None |
PREA |
| Escitalopram – Lexapro |
AbbVie Inc. |
Medical (PDF – 6 MB) |
None |
None |
PREA |
| Eslicarbazepine acetate – Aptiom |
Sunovion Pharmaceutical Inc. |
CDTL Review (PDF – 593 KB)
Medical (PDF – 5 MB)
|
Clinical pharmacology (PDF – 2.9 KB) |
None |
PREA |
| Eszopiclone – Lunesta |
Sunovion Pharmaceuticals, Inc. |
Medical (PDF – 1MB) |
Clinical pharmacology (PDF -883KB) |
None |
BOTH |
| Etafilcon – Theravision with Ketotifen |
Johnson & Johnson Vision Care, Inc. |
DD Review (PDF – 2 MB)
Medical (PDF – 460 KB)
|
None |
Statistical (PDF – 3 MB) |
PREA |
| Etanercept – Enbrel |
Immunex Corporation, a wholly-owned subsidiary of Amgen Inc. |
Medical (PDF – 4.8 MB)
DD Review (PDF – 568 KB)
CDTL Review PDF – 504 KB)
|
Clinical pharmacology (PDF – 702 KB) |
Statistical (PDF – 444 KB) |
PREA |
| Etanercept – Enbrel |
Amgen Inc. |
Medical (PDF – 4 MB) |
None |
None |
PREA |
| Etanercept-szzs – Erelzi |
Sandoz Inc. |
Medical (PDF – 1.7 MB) |
Clinical pharmacology (PDF – 4.7 MB) |
Statistical (PDF – 432 KB) |
PREA |
Etanercept-szzs – Erelzi |
Sandoz Inc. |
CDTL Review PDF – 504 KB)
|
None |
None |
PREA |
Etanercept-szzs – Erelzi |
Sandoz Inc. |
Medical (PDF – 2 MB) |
None |
None |
PREA |
| Etravirine – Intelence |
Janssen Products, LP |
Medical (PDF -1.4MB) |
Clinical pharmacology (PDF -1.7MB) |
None |
BOTH |
| Etravirine – Intelence |
Janssen Products, LP |
Medical (PDF -1 MB) |
Clinical pharmacology (PDF – 896 KB) |
None |
BOTH |
| Everolimus tablets for oral suspension – Afinitor Disperz |
Novartis Pharmaceuticals Corporation |
Medical (PDF -10MB) |
Clinical pharmacology (PDF -2MB) |
None |
BPCA |
| Evolocumab – Repatha |
Amgen, Inc. |
Medical (PDF – 5 MB) |
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF – 1 MB) |
PREA |
| Exenatide – Bydureon |
AstraZeneca Pharmaceuticals AB C/O AstraZeneca Pharmaceuticals LP |
Medical (PDF – 3 MB) |
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF – 1 MB) |
BOTH |
| Exenatide – Byetta |
AstraZeneca AB |
Medical (PDF – 802 KB) |
Clinical pharmacology (PDF – 14 KB) |
Statistical (PDF – 122 KB) |
BOTH |
Fenfluramine HCl – Fintepla |
Zogenix, Inc. |
Medical (PDF – 588 KB) |
Clinical pharmacology (PDF – 2 MB) |
None |
BPCA |
| Ferric oxyhydroxide – Velphoro |
Vifor Fresenius Medical Care Renal Pharma France |
Medical (PDF – 1 MB) |
None |
None |
BPCA |
| Ferric carboxymaltose -Injectafer |
American Regent, Inc. |
Medical (PDF – 613 KB) |
Clinical pharmacology (PDF – 7 MB) |
None |
PREA |
| Fesoterodine fumarate – Toviaz |
Pfizer, Inc. |
Medical (PDF – 4 MB) |
Clinical pharmacology (PDF – 6 MB) |
Statistical (PDF – 300 KB) |
PREA |
|
Fidaxomicin – Dificid
|
Cubist Pharmaceuticals LLC |
Medical (PDF -3.8MB) |
None |
None |
BPCA |
| Filgrastim-sndz – Zarxio |
Sandoz, Inc. |
Medical (PDF -3.8MB)
DD Review (PDF -86KB)
TL Review (PDF -422KB)
|
Clinical pharmacology (PDF -2.75MB)
Addendum (PDF – 1.1MB)
|
Statistical (PDF -6742KB) |
PREA |
| Filgrastim-aafi – Nivestym |
Hospira, Inc. |
CDTL Review (PDF – 746 KB)
Medical (PDF – 245 KB)
|
Clinical pharmacology (PDF – 661 KB) |
Statistical (PDF – 377 KB) |
PREA |
| Finafloxacin otic suspension – Xtoro |
Alcon Research, Ltd. |
Medical (PDF -6.8MB) |
Clinical pharmacology (PDF -2MB) |
Statistical (PDF -3.2MB) |
BOTH |
| Fingolimod – Gilenya |
Novartis Pharmaceuticals Corporation |
CDTL Review (PDF – 2 MB)
Medical (PDF – 3.8 MB)
|
Clinical pharmacology (PDF -2MB) |
Statistical (PDF -3.2MB) |
BOTH |
| Fingolimod – Tascenso ODT |
Handa Neuroscience, LLC |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
| Fluticasone furoate inhalation powder – Arnuity Ellipta |
GlaxoSmithKline |
Medical (PDF -8.6MB) |
Clinical pharmacology (PDF -5.7MB) |
Statistical (PDF -1.9) |
PREA |
| Fluticasone furoate – Arnuity Ellipta |
GlaxoSmithKline |
Medical (PDF – 956 KB) |
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF – 507 KB) |
PREA |
| Fluticasone furoate – Arnuity Ellipta |
GlaxoSmithKline Intellectual Property Development Ltd. England |
Medical (PDF – 956 KB) |
None |
None |
PREA |
| Fluticasone furoate – Flonase Sensimist Allergy Relief |
Haleon US Holdings |
Medical (PDF – 489 KB) |
None |
Statistical (PDF – 133 KB) |
PREA |
| Fluticasone Furoate/Umeclidinium/Vilanterol – Trelegy Ellipta |
GlaxoSmithKline Intellectual Property Development Ltd. England |
Medical (PDF – 3MB) |
None |
None |
PREA |
Fluticasone furoate/vilanterol – Breo Ellipta |
GlaxoSmithKline |
Medical (PDF – 16 MB) |
Clinical pharmacology (PDF – 5 MB) |
Statistical (PDF – 4 MB) |
PREA |
| Fluticasone furoate and vilanterol – Breo Ellipta |
GlaxoSmithKline Intellectual Property Development Ltd. England C/o GlaxoSmithKline Research & Development |
Medical (PDF – 6 MB) |
None |
None |
BPCA |
| Fluticasone propionate Lotion – Cutivate |
Fougera Pharmaceuticals Inc. |
Medical (PDF -1.2MB) |
Clinical pharmacology (PDF -1.4MB) |
None |
PREA |
| Fluticasone propionate/salmeterol xinafoate – Advair HFA |
GlaxoSmithKline |
Medical (PDF -1 MB) |
Clinical pharmacology (PDF -267KB) |
Statistical (PDF -52 KB) |
PREA |
| Fluticasone propionate – ArmonAir RespiClick |
Teva Pharmaceutical Industries Ltd. |
Medical (PDF -10 MB) |
Clinical pharmacology (PDF – 4.3MB) |
Statistical (PDF -1.2 KB) |
PREA |
|
Fluticasone propionate – ArmonAir RespiClick
|
Teva Pharmaceutical Industries Ltd. c/o: Teva Branded Pharmaceutical Products R&D Inc. |
Medical (PDF – 6 MB) |
None |
None |
BOTH |
| Fluticasone propionate/salmeterol – AirDuo |
Teva Pharmaceutical Industries Ltd. |
Medical (PDF -10 MB) |
Clinical pharmacology (PDF – 4.3 MB) |
Statistical (PDF -1.2 KB) |
PREA |
|
Formoterol fumarate and mometasone furoate – Dulera
|
Merck Sharp & Dohme Corp. |
Medical (PDF – 10 MB) |
None |
None |
BOTH |
| Fosaprepitant – Emend |
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 7 MB) |
Statistical (PDF – 662 KB) |
BOTH |
Fosaprepitant – Focinvez |
Spes Pharmaceuticals Inc. |
Unireview (PDF – 248 MB)
Unireview (PDF – 1 MB)
|
None |
None |
PREA |
| Fosphenytoin sodium – Cerebyx |
Parke-Davis, a Division of Pfizer, Inc. |
CDTL Review (PDF – 390 KB)
Medical (PDF – 1.5 MB)
|
Clinical pharmacology (PDF – 5 MB) |
None |
BPCA |
| Gadobutrol – Gadavist |
Bayer HealthCare Pharmaceuticals, Inc. |
Medical (PDF – 958KB) |
Clinical pharmacology (PDF -2.2MB) |
Statistical (PDF -422 KB) |
PREA |
| Gadobutrol – Gadavist |
Bayer Healthcare Pharmaceuticals, Inc. |
Medical (PDF – 7MB) |
None |
Statistical (PDF -782 KB) |
PREA |
|
Gadopiclenol – Elucirem
|
Guerbet LLC |
Medical (PDF – 3 MB) |
None |
None |
PREA |
| Gadoterate meglumine – Dotarem |
Guerbet LLC |
Medical (PDF – 3MB) |
Clinical pharmacology (PDF -768KB) |
Statistical (PDF -1.2 MB) |
PREA |
| Gadoterate meglumine – Dotarem |
Guerbet LLC |
Medical (PDF 1.3 MB) |
Clinical pharmacology (PDF – 1.5 MB) |
Statistical (PDF – 398 KB) |
PREA |
| Gadoteridol – ProHance |
Bracco Diagnostics, Inc |
Medical (PDF – 3 MB) |
None |
None |
PREA |
| Gadoxetate disodium – Eovist |
Bayer HealthCare Pharmaceuticals, Inc. |
Medical (PDF -1.2MB) |
Clinical pharmacology (PDF -1.5MB) |
None |
PREA |
| Gatifloxacin ophthalmic solution – Zymar |
Allergan, Inc. |
Medical (PDF – 78 KB) |
None |
None |
BPCA |
| Gatifloxacin – Zymar |
Allergan, Inc. |
DDTL (PDF – 428 KB) |
None |
None |
Both |
|
Gepirone – Exxua
|
Fabre-Kramer Pharmaceuticals, Inc. |
Medical (PDF – 10 MB) |
None |
None |
Both |
| Glecaprevir and Pibrentasvir – Mavyret |
AbbVie Inc. |
CTDL (PDF – 2 MB)
CTDL Addendum (PDF – 187 KB)
|
Clinical pharmacology (PDF – 409 KB) |
Statistical (PDF – 439 KB) |
PREA |
| Glecaprevir and Pibrentasvir – Mavyret |
AbbVie Inc. |
Medical (PDF – 78 KB) |
None |
None |
PREA |
| Glecaprevir and pibrentasvir – Mavyret |
AbbVie, Inc. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 3 MB) |
None |
BOTH |
| Glucagon – Gvoke |
Xeris Pharmaceuticals, Inc. |
Medical (PDF – 3 MB)
CTDL Review (PDF – 3 MB
|
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF – 2 MB) |
PREA |
| Glucagon – Baqsimi |
Eli Lilly and Company |
Medical (PDF – 3 MB)
CTDL Review (PDF – 3 MB
|
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF – 2 MB) |
PREA |
| Glycopyrronium – Qbrexza |
Dermira, Inc. |
Medical (PDF – 6 MB) |
None |
None |
PREA
|
| Golimumab – Simponi |
Janssen Biotech, Inc. |
Medical (PDF – 3.1 MB)
|
Clinical pharmacology (PDF – 307 KB) |
Statistical (PDF – 1.1 MB) |
PREA |
| Golimumab – Simponi Aria |
Janssen Biotech, Inc. |
Medical (PDF – 4 MB) |
None |
None |
PREA |
| Guanfacine – Intuniv |
Shire |
Medical (PDF – 2 MB)
CTDL Review (PDF -134 KB)
|
Clinical pharmacology (PDF – 330 KB) |
Statistical (PDF – 544 KB) |
Both |
| Guanfacine – Intuniv |
Shire |
Medical (PDF -3MB) |
Clinical pharmacology (PDF – 667KB) |
Statistical (PDF -3MB) |
PREA |
| Halobetasol – Propionate Ultravate |
Sun Pharmaceutical Industries, Inc. |
Medical (PDF – 150 KB) |
Clinical pharmacology (PDF – 303 KB) |
None |
PREA |
|
Halobetasol Propionate – Lexette
|
Mayne Pharma LLC |
Medical (PDF – 249 KB) |
Clinical pharmacology (PDF – 752 KB) |
None |
BOTH |
| Ibrexafungerp – Brexafemme |
SCYNEXIS, Inc. |
Medical (PDF – 10 MB) |
None |
None |
PREA |
| Ibrexafungerp – Brexafemme |
SCYNEXIS, Inc. |
Medical (PDF – 1 MB) |
None |
None |
PREA |
| Ibrutinib – Imbruvica |
Pharmacyclics LLC |
Medical (PDF – 20 MB) |
None |
None |
BPCA |
| Ibuprofen – Caldolor |
Cumberland Pharmaceuticals, Inc. |
CTDL Review (PDF -134 KB) |
Clinical pharmacology (PDF – 752 KB) |
None |
PREA |
| Ibuprofen – Caldolor |
Cumberland Pharmaceuticals, Inc. |
DD Summary Review (PDF -669KB)
Medical (PDF -3MB)
|
Clinical pharmacology (PDF -3.7MB) |
Statistical (PDF -378KB) |
PREA |
| IncobotulinumtoxinA – Xeomin |
Merz Pharmaceuticals GmbH |
Medical (PDF – 2 MB) |
None |
Statistical (PDF – 1 MB) |
PREA |
| incobotulinumtoxinA – Xeomin |
Merz Pharmaceuticals GmbH |
Medical (PDF – 1 MB) |
None |
Statistical (PDF – 872 KB) |
PREA |
|
Indocyanine green for Injection – Spy Agent Green
|
Novadaq Technologies ULC |
Medical (PDF – 4 MB) |
None |
None |
PREA |
| Infliximab-axxq – Avsola |
Amgen, Inc. |
Medical (PDF – 4 MB) |
None |
None |
PREA |
| Infliximab-dyyb – Inflectra |
Celltrion, Inc. |
Medical (PDF -5.3MB)
Addendum (PDF – 1MB)
|
None |
Statistical (PDF -2MB) |
PREA |
| Infliximab-abda – Renflexis |
Samsung Bioepsis Co., Ltd |
CDTL Review (PDF – 1 MB)
Medical (PDF – 3.5 MB)
Medical 2(PDF – 267 KB)
Medical 3 (PDF – 93 KB)
|
Clinical pharmacology (PDF – 7.7 MB) |
Statistical (PDF – 959 KB)
Statistical 2 (PDF – 602 KB)
|
PREA |
| Insulin aspart injection – Fiasp |
Novo Nordisk Inc. |
CDTL Review (PDF – 1 MB)
Medical (PDF – 3.5 MB)
|
Clinical pharmacology (PDF – 4MB) |
Statistical (PDF – 905KB) |
PREA |
| Insulin Degludec – Tresiba |
Novo Nordisk Inc. |
CDTL Review (PDF – 7MB)
Medical (PDF – 7 MB)
|
Clinical pharmacology (PDF – 4MB) |
Statistical (PDF – 905KB) |
PREA |
| Insulin Degludec / Insulin Aspart) – Ryzodeg |
Novo Nordisk Inc. |
Medical (PDF – 7 MB) |
Clinical pharmacology (PDF – 4 MB) |
Statistical (PDF – 905 KB) |
PREA |
|
Insulin glargine-yfgn – Semglee
|
Mylan Pharmaceuticals Inc. |
Medical (PDF – 8 MB) |
None |
None |
PREA |
| Insulin glargine-aglr – Rezvoglar |
Eli Lilly and Company |
Medical (PDF – 2 MB) |
None |
None |
PREA |
Insulin lispro-aabc – Lyumjev |
Eli Lilly and Company |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 10 MB)
Clinical pharmacology addendum (PDF – 10 KB)
|
Statistical (PDF – 253 KB) |
PREA |
| Iodixanol – Visipaque |
GE HealthCare Inc.
|
CDTL Review (PDF – 2 MB)
Medical (PDF – 2 MB)
|
Clinical pharmacology (PDF – 988 KB) |
Statistical (PDF – 1.8 MB) |
PREA |
| Iohexol – Oraltag |
Interpharma Praha, a.s. |
Medical (PDF – 91 KB) |
Clinical pharmacology (PDF – 294 KB) |
Statistical (PDF – 98 KB) |
PREA |
| Ipilimumab – Yervoy |
Bristol-Myers Squibb Company |
Medical (PDF 6 MB) |
Clinical pharmacology (PDF – 1.6 MB) |
None |
BPCA |
| Iron Sucrose Injection, USP – Venofer |
Luitpold Pharmaceuticals, Inc. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 114 KB) |
Statistical (PDF – 576 KB) |
PREA |
| Isavuconazonium sulfate – Cresemba |
Astellas Pharma US Inc. |
Medical (PDF – 5 MB) |
None |
None |
BPCA |
| Ivabradine – Corlanor |
Amgen Inc. |
CDTL (PDF – 3 MB)
Medical (PDF – 4 MB)
|
Clinical pharmacology (PDF – 4 MB) |
Statistical (PDF – 51 KB) |
BPCA |
| Ivacaftor – Kalydeco |
Vertex Pharmaceuticals Incorporated |
Medical (PDF – 4 MB) |
None |
None |
BPCA |
| Ixekizumab – Taltz |
Eli Lilly and Company |
Medical (PDF – 2 MB) |
None |
None |
PREA |
| Kit for the preparation of technetium Tc 99m-labeled carbon inhalation aerosol – Technegas |
Cyclomedica Australia Pty Ltd. |
Medical (PDF – 1 MB) |
None |
None |
PREA |
| Kit for the Preparation of Technetium Tc 99m Pentetate Injection – Draximage |
Jubilant DraxImage, Inc |
Medical (PDF – 2 MB) |
None |
Statistical (PDF – 1 MB) |
PREA |
| Lacosamide – Motpoly XR |
Aucta Pharmaceuticals, Inc. |
Medical (PDF – 276 KB) |
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
| Lacosamide – Vimpat |
UCB, Inc. |
CDTL Review (PDF – 371 KB)
Medical (PDF – 915 KB)
|
Clinical pharmacology (PDF – 2 MB) |
None |
PREA
|
| Lacosamide – Vimpat |
UCB, Inc. |
Medical (PDF – 541 KB)
Medical (PDF – 631 KB)
|
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF – 2 MB) |
PREA |
| Lacosamide – Vimpat |
UCB, Inc. |
Medical (PDF – 700 KB) |
Clinical pharmacology (PDF – 800 KB) |
None |
PREA |
| Lacosamide – Vimpat |
UCB, Inc. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF – 9 MB) |
PREA |
| Lactic acid citric acid and K bitartrate – Phexxi |
Evofem, Inc. |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 1 KB) |
Statistical (PDF – 3 76706 KB) |
PREA |
| Lamivudine – Epivir |
ViiV Healthcare Company |
Medical (PDF -4.2 MB) |
Clinical pharmacology (PDF – 3 MB) |
|
PREA |
| Lamivudine and Raltegravir – Dutrebis |
Merck Sharp & Dohme Corp. |
Medical (PDF -1 MB) |
Clinical pharmacology (PDF – 6.4 MB) |
None |
PREA |
| Lamivudine and tenofovir – Cimduo |
Mylan Pharmaceuticals India |
Medical (PDF – 73 KMB) |
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
|
Lamivudine and tenofovir disoproxil fumarate – Temixys
|
Celltrion, Inc. |
Medical (PDF – 20 KB)
|
Clinical pharmacology addendum (PDF – 166 KB)
Clinical pharmacology (PDF – 1 MB)
|
None |
PREA |
| Lamotrigine – Lamictal |
GlaxoSmithKline LLC |
Medical (PDF -18 MB) |
Clinical pharmacology (PDF – 793 KB) |
Statistical (PDF – 1.8 MB) |
PREA |
| Lanadelumab-flyo – Takhzyro |
Takeda Pharmaceuticals U.S.A., Inc. |
Medical (PDF – 7 MB) |
None |
None |
BPCA |
| Ledipasvir-sofosbuvir – Harvoni |
Gilead Sciences, Inc. |
Medical and CDTL (PDF – 1.5 MB) |
Clinical pharmacology (PDF – 539 KB) |
Statistical (PDF – 205 KB) |
PREA |
| Ledipasvir-sofosbuvir – Harvoni |
Gilead Sciences, Inc. |
Medical (PDF – 426 KB) |
None |
None |
BOTH |
| Leuprolide acetate – Fensolvi |
Tolmar, Inc. |
Medical (PDF – 280 KB) |
Clinical pharmacology (PDF – 4 MB |
Statistical (PDF – 2 MB) |
PREA |
| Levalbuterol hydrochloride – Xopenex |
Oak Pharmaceuticals |
Medical (PDF – 8 MB) |
Clinical pharmacology (PDF – 4 MB) |
Statistical (PDF – 2 MB) |
PREA |
| Levalbuterol tartrate – Xopenex HFA |
Sunovion Pharmaceuticals Inc. |
Medical (PDF – 4 MB) |
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF 1 MB) |
PREA |
| Levamlodipine – Conjupri |
CSPC Ouyi Pharmaceutical Co., Ltd. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 569 KB) |
None |
PREA |
| Levetiracetam – Keppra Extended Release Tablets |
UCB, Inc. |
DD Summary Review (PDF – 202 KB)
CDTL Review (PDF – 371 KB)
Medical (PDF – 327 KB)
|
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
| Levomilnacipran – Fetzima |
AbbVie Inc. |
Medical (PDF – 4 MB) |
None |
None |
PREA |
| Levonorgestrel – Liletta |
Medicines360 |
Medical (PDF – 9 MB) |
Clinical pharmacology (PDF – 1 MB)
Clinical pharmacology (PDF – 2 MB)
|
Statistical (PDF – 2 MB) |
PREA |
| Levonorgestrel/ethinyl estradiol tablets |
Exeltis |
CDTL (PDF – 9 MB)
Medical (PDF – 9 MB)
Medical (PDF – 9 MB)
|
Clinical pharmacology (PDF – 1 MB)
Clinical pharmacology (PDF – 4 MB)
|
Statistical (PDF – 1.5 MB) |
PREA |
| Levonorgestrel/ethinyl estradiol and ethinyl estradiol – Quartette |
Teva Branded Pharmaceutical Products R&D, Inc. |
Medical (PDF – 5 MB) |
Clinical pharmacology (PDF – 4 MB)
Clinical pharmacology addendum (PDF – 89KB)
|
Statistical (PDF – 1MB) |
PREA |
| Levonorgestrel-releasing intrauterine system – Skyla |
Bayer HealthCare Pharmaceuticals, Inc. |
Medical (PDF – 8MB) |
Clinical pharmacology (PDF – 4MB) |
Statistical (PDF – 424 KB) |
PREA |
|
Levonorgestrel releasing intrauterine system – Liletta
|
Medicines360 |
CDTL Review (PDF – 179KB)
Medical (PDF – 2 MB)
|
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF – 168 KB) |
PREA |
|
Levonorgestrel – Mirena
|
Bayer HealthCare Pharmaceuticals, Inc. |
Medical (PDF – 2 MB) |
None |
None |
PREA |
| Levothyroxine sodium oral solution – Tirosint-SOL |
Cromsource, Inc. |
CDTL Review (PDF – 461 KB)
Medical (PDF – 3 MB)
|
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
| Linaclotide – Linzess |
AbbVie Inc. |
Medical (PDF – 3 MB) |
None |
None |
BOTH |
| Linagliptin and Metformin Hydrochloride – Jentadueto XR |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Medical (PDF – 7 MB) |
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF – 246 KB) |
BOTH |
| Linagliptin and Metformin hydrochloride – Tradjenta |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Medical (PDF – 7 MB) |
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF – 246 KB) |
BOTH |
| Linagliptin – Tradjenta |
Boehringer Ingelheim Pharmaceuticals, Inc |
Medical (PDF – 7 MB) |
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF – 2 MB) |
BOTH |
| Lipid injectable emulsion – SMOFlipid |
Fresenius Kabi USA, LLC |
Medical (PDF – 3 MB) |
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
|
Liraglutide – Saxenda
|
Novo Nordisk, Inc. |
Medical (PDF – 5 MB) |
Clinical pharmacology (PDF – 5 MB) |
Statistical (PDF – 2 MB) |
PREA |
| Liraglutide – Victoza |
Novo Nordisk Inc. |
Medical (PDF – 8 MB) |
Clinical pharmacology (PDF – 864 KB) |
Statistical (PDF – 450 KB) |
BOTH |
| Lisdexamfetamine dimesylate – Vyvanse |
Shire Development, LLC |
Medical (PDF – 218 KB) |
Clinical pharmacology (PDF – 1 MB) |
None |
BOTH |
| Lisdexamfetamine mesylate – Vyvanse |
Shire |
Medical (PDF – 2 MB) |
None |
Statistical (PDF – 1 MB) |
PREA |
|
Lisdexamfetamine dimesylate – Vyvanse
|
Takeda Pharmaceuticals U.S.A., Inc. |
Medical (PDF – 804 KB) |
None |
None |
BOTH |
Lisenatide – Adlyxin |
Sanofi-aventis U.S. LLC |
Medical (PDF – 182 KB) |
Clinical pharmacology (PDF – 1 MB) |
None |
BOTH |
Lumacaftor and ivacaftor – Orkambi |
Vertex Pharmaceuticals Incorporated |
Medical (PDF – 6 MB) |
None |
None |
BPCA |
| Loteprednol – Lotemax |
Bausch & Lonb Inc. |
Medical (PDF – 318 KB)
Medical (PDF – 218 KB)
|
None |
Statistical (PDF – 3 MB) |
PREA |
| Luliconazole – LuzuTM |
Medicis Pharmaceutical Corporation, a division of Valeant Pharmaceuticals NA LLC |
CDTL (PDF – 358 KB)
CDTL (PDF – 372 KB)
Medical (PDF – 306 KB)
Medical (PDF – 616 KB)
|
Clinical pharmacology (PDF -1 MB)
Clinical pharmacology (PDF – 423 KB)
|
Statistical (PDF – 207 KB) |
PREA |
| Lopinavir / Ritonavir – Kaletra |
AbbVie Inc. |
Medical (PDF – 5.8 MB) |
Clinical pharmacology (PDF -2.3 MB) |
Statistical (PDF – 2 MB) |
PREA |
| Lubiprostone – Amitizia |
Sucampo Pharmaceuticals Inc. |
Medical (PDF – 11 MB) |
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF – 1 MB) |
PREA |
| Lutetium Lu177 dotatate – Lutathera |
Advanced Accelerator Applications USA, Inc. |
Medical (PDF – 3 MB) |
None |
None |
BPCA |
| Lurasidone hydrochloride – Latuda |
Sunovion Pharmaceuticals, Inc. |
Medical (PDF – 6 MB)
Medical (PDF – 7 MB)
|
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 369 KB)
Statistical (PDF – 255 KB)
|
BOTH |
| Lurasidone hydrochloride – Latuda |
Sunovion Pharmaceuticals, Inc. |
CDTL (PDF – 6 MB)
Medical (PDF – 6 MB)
|
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF – 368 KB) |
PREA |
| Lurasidone hydrochloride – Latuda |
Sunovion Pharmaceuticals, Inc. |
Medical (PDF – 1 MB) |
None |
None |
PREA |
| Maraviroc – Selzentry |
Viiv Healthcare |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 3 MB) |
None |
PREA |
| Maraviroc – Selzentry |
Viiv Healthcare |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 3 MB) |
None |
BPCA |
| Memantine hydrochloride – Namenda XR |
Forest Research Institute, Inc. (subsidiary of Forest Laboratories Inc.) |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 956 KB) |
Statistical (PDF – 1 MB) |
BPCA |
| Mepolizumab – Nucala |
GlaxoSmithKline LLC |
Medical (PDF – 8 MB) |
Clinical pharmacology (PDF – 6 MB)
Clinical pharmacology addendum (PDF – 425 KB)
|
Statistical (PDF – 1 MB) |
PREA |
| Mepolizumab – Nucala |
GlaxoSmithKline LLC |
Medical(PDF – 8 MB) |
None |
None |
PREA |
| Mepolizumab – Nucala |
GlaxoSmithKline LLC |
Medical (PDF – 8 MB) |
None |
None |
PREA |
| Mirabegron – Myrbetriq |
Astellas Pharma Global Development, Inc. |
Medical (PDF – 13 MB) |
Clinical pharmacology (PDF – 3 MB)
|
Statistical (PDF – 168KB) |
BOTH |
| Mesalamine – Asacol HD |
Warner Chilcott |
Medical (PDF – 6 MB) |
Clinical pharmacology (PDF – 3 MB)
Clinical pharmacology (PDF – 518 KB)
|
Statistical (PDF -499 KB) |
PREA |
| Mesalamine – Canasa |
Forest Laboratories |
Medical (PDF – 6 MB) |
Clinical pharmacology (PDF – 251 KB) |
Statistical (PDF – 344 KB) |
PREA |
| Mesalamine – Delzicol |
Warner Chilcott LLC |
Medical (PDF – 707 KB)
Medical Addendum(PDF – 495 KB)
|
Clinical pharmacology (PDF – 116 KB) |
None |
PREA |
| Mesalamine – Delzicol |
Warner Chilcott (US), LLC |
Medical (PDF – 5 MB) |
Clinical pharmacology (PDF – 729 KB) |
Statistical (PDF – 1 KB) |
PREA |
| Mesalamine – Lialda |
Shire Development, LLC |
Medical (PDF – 6 MB) |
None |
None |
PREA |
|
Metformin hydrochloride for extended-release oral suspension – Riomet ER
|
Pharmaceutical Industries Limited |
CTDL Review (PDF – 917 KB) |
Clinical pharmacology (PDF – 818 KB) |
None |
PREA |
| 10% Methyl salicylate, 3% L-menthol – Salonpas Pain Relief |
Hisamitsu Pharmaceutical Co., Inc. |
Medical (PDF – 998 KB)
Medical (PDF – 3 MB)
|
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 1 MB) |
PREA |
|
Methylphenidate hydrochloride extended-release – Aptensio XR
|
Rhodes Pharmaceuticals L.P. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 4 MB) |
Statistical (PDF – 1 MB) Statistical (PDF – 629 KB) |
PREA |
| Methylphenidate hydrochloride – Aptensio XR |
Rhodes Pharmaceuticals L.P. |
CTDL Review (PDF – 592 KB)
Medical (PDF – 3 MB)
|
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF – 1 MB)
Statistical (PDF – 139 KB)
|
BOTH |
| Methylphenidate hydrochloride – Quillivant XR |
NextWave Pharmaceuticals, Inc. |
Medical (PDF – 26 KB) |
Clinical pharmacology (PDF – 588 KB) |
Statistical (PDF – 380 KB) |
PREA |
| Methylphenidate hydrochloride extended release chewable tablets – QuilliChew ER |
Pfizer Inc. |
CTDL Review (PDF -1 MB)
Medical (PDF – 5 MB)
|
Clinical pharmacology (PDF -2.9MB) |
Statistical (PDF -498KB) |
PREA |
|
Methylphenidate HCL extended-release capsules – Adhansia XR
|
Purdue Pharma
|
Medical (PDF – 2 MB)
Medical (PDF – 5 MB)
|
Clinical pharmacology (PDF – 2 MB)
|
Statistical (PDF – 1 MB)
Statistical (PDF – 2 MB)
|
PREA |
|
Methylphenidate hydrochloride – Jornay PM
|
Ironshore Pharmaceuticals & Development, Inc. |
Medical (PDF – 4.8 MB) |
Clinical pharmacology (PDF – 2.1 MB) |
Statistical (PDF – 921 KB) |
PREA |
| Methylphenidate extended-release orally disintegrating tablets – Cotempla XR-ODT |
Neos Therapeutics, Inc. |
Medical (PDF – 5.7 MB)
Medical (PDF – 1.2 MB)
|
Clinical pharmacology (PDF – 2.1 MB)
Clinical pharmacology (PDF – 2.1 MB)
|
Statistical (PDF – 921 KB)
Statistical (PDF – 96 KB)
|
PREA |
| Methoxy polyethylene glycol-epoetin beta – Mircera |
Vifor International AG |
Medical (PDF – 2.3 MB)
|
None |
Statistical (PDF – 239 KB)
|
PREA |
| Methoxy polyethylene glycol-epoetin beta – Mircera |
Vifor (International) AG c/o ProPharma Group |
Medical (PDF – 7 MB) |
Clinical Pharmacology (PDF – 5MB) |
Statistical (PDF – 7 MB) |
PREA |
| Metoprolol Succinate – KAPSPARGO SPRINKLE |
Sun Sun Pharmaceutical Industries LimitedPharmaceutical Industries Limited |
Medical (PDF – 799 KB) |
Clinical pharmacology (PDF – 978 KB) |
None |
PREA |
| Metronidazole – Likmez |
Saptalis Pharmaceuticals, LLC |
Medical (PDF – 6 MB) |
None |
None |
PREA |
| Metronidazole vaginal gel 1.3% – Nuvessa |
Chemo Research SL |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 70 KB) |
Statistical (PDF – 127 KB) |
PREA |
| Micafungin for injection – Mycamine |
Astellas Pharma US, Inc. |
Medical (PDF – 1 MB) |
None |
None |
BOTH |
|
Micafungin in Sodium Chloride Injection – Micafungi
|
Baxter HealthCare Corporation |
Medical (PDF – 1 MB) |
None |
None |
PREA |
| Micafungin sodium – Mycamine |
Astellas Pharma US, Inc. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 4.4MB)
|
Statistical (PDF -987KB) |
BPCA |
Minocycline – Amzeeq |
Foamix Pharmaceuticals Inc. |
Medical (PDF – 2.2 MB) |
None |
None |
PREA |
| Mirabegron extended-release tablets and mirabegron extended-release for oral suspension – Myrbetriq and Myrbetriq Granules |
Astellas Pharma Global Development, Inc. |
Medical (PDF – 13 MB) |
None |
None |
BOTH |
| Mixed salts of a single-entity amphetamine product – Mydayis |
Shire Development, LLC. |
Medical (PDF – 7 MB)
|
Clinical pharmacology (PDF -1.8KB) |
Statistical (PDF -987KB) |
PREA |
| Mixed salts of a single entity amphetamine product – Mydayis |
Shire Development, LLC. |
Medical (PDF – 7 MB) |
None |
None |
BPCA |
| Mometasone furoate – Asmanex HFA |
Merck Sharp & Dohme Corp. |
Medical (PDF – 3 MB) |
Clinical pharmacology (PDF -2 MB) |
Statistical (PDF -603KB) |
PREA |
| Mometasone furoate – Asmanex HFA |
Merck Sharp & Dohm Corp |
Medical (PDF- 1 MB) |
None |
None |
PREA |
| Mometasone furoate – Asmanex HFA |
Merck Sharp & Dohm Corp |
Medical (PDF – 1 MB) |
None |
None |
PREA |
| Mometasone furoate and formoterol fumarate – Dulera |
Schering-Plough |
Medical (PDF- 1 MB) |
None |
None |
PREA |
| Morphine sulfate – Morphine sulfate |
Hospira, Inc. |
Medical (PDF – 1 MB) |
None |
None |
PREA |
| Morphine sulfate – Morphine sulfate |
Hikma Pharmaceuticals USA Inc. |
Medical (PDF – 5 MB) |
Clinical pharmacology (PDF – 3 MB) |
None |
PREA |
|
Moxifloxacin – Avelox
|
Bayer Pharmaceuticals |
Medical (PDF- 905 KB) |
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF – 760 KB) |
PREA |
| Moxifloxacin ophthalmic solution – Vigamox |
Alcon Pharmaceuticals, Ltd. |
Medical (PDF – 434 KB)
DD Summary Review (PDF- 118 KB)
|
None |
None |
BPCA |
Mycophenolate mofetil – CellCept |
Roche Palo Alto LLC |
Medical (PDF – 6 MB) |
None |
None |
PREA |
| Naftifine hydrochloride – Naftin |
Merz Pharmaceuticals, LLC |
Medical (PDF – 488 KB) |
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF – 188 KB) |
PREA |
| Naftifine hydrochloride – Naftin Cream, 2% |
Merz Pharmaceuticals, LLC |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF – 822 KB) |
PREA |
| Nalmefene – Opvee |
Opiant Pharmaceuticals, Inc. |
CTDL Review (PDF – 4 MB)
|
Clinical pharmacology (PDF – 9 MB)
Clinical pharmacology addendum (PDF – 9 KB)
|
Statistical (PDF – 2 MB) |
PREA |
| Naloxone hydrochloride – Kloxxado
|
Hikma Pharmaceuticals USA, Inc. |
CTDL Review (PDF – 613 KB)
CTDL and DD Review (PDF – 1 MB)
Medical (PDF – 4 MB)
|
None |
None |
PREA |
| Naloxone hydrochloride – Narcan Nasal Spray |
Adapt Pharma Operations Limited |
DD Summary Review(PDF -1 MB)
CTDL Review (PDF – 3 MB)
|
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
| Naloxone Hydrochloride Injection – Naloxone Hydrochloride Injection |
Kaleo, Inc. |
CDTL Review (PDF – 2 MB) |
Clinical pharmacology (PDF – 4 MB) |
None |
PREA |
| Naloxone Hydrochloride – Rextovy |
Amphastar Pharmaceuticals, Inc |
Medical (PDF – 3 MB)
CDDD Review (PDF – 637 KB)
|
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
| Naloxone Hydrochloride – Rezenopy |
Summit Biosciences |
Medical (PDF – 2MB)
CDTL Review (PDF – 3MB)
|
Clinical pharmacology (PDF – 1MB) |
None |
PREA |
| Naloxone hydrochloride – RiVive |
Harm Reduction Therapeutics, Inc. |
Medical (PDF – 2 MB) |
None |
None |
PREA |
|
Naloxone hydrochloride – Zimhi
|
Adamis Pharmaceuticals Corporation |
CDTL Review (PDF – 2 MB) |
Clinical pharmacology (PDF – 368 KB) |
None |
PREA |
| Naproxen sodium 220 mg and Diphenhydramine hydrochloride – Aleve PM |
Bayer HealthCare, LLC – Consumer Care |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF -1 MB) |
PREA |
| Naproxen and esomeprazole magnesium – Vimovo |
Horizon Pharma Inc. |
Medical (PDF – 4 MB) |
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
| Neostigmine methylsulfate – Bloxiverz |
Eclat Pharmaceuticals, LLC |
Medical (PDF – 8 MB) |
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
| Neostigmine methylsulfate and glycopyrrolate – Prevduo |
Slayback Pharma LLC |
CDTL Review (PDF – 794 KB) |
Clinical pharmacology (PDF – 284 KB) |
None |
PREA |
| Nevirapine – Viramune XR |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Medical (PDF -2MB) |
Clinical pharmacology (PDF – 446 KB) |
Statistical (PDF – 723KB) |
PREA |
| Nilotinib – Tasigna |
Sponsor: Novartis Pharmaceuticals Corporation |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 1.6 MB) |
Statistical (PDF – 124 KB) |
BPCA |
| Nintedanib – Ofev |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Medical (PDF – 10 MB) |
None |
None |
BPCA |
| Nirmatrelvir – Ritonavir – Paxlovid |
Pfizer, Inc |
Medical (PDF – 27 MB) |
None |
None |
PREA |
| Nirsevimab-alip – Beyfortus |
AstraZeneca AB |
Medical (PDF – 20 MB) |
None |
None |
PREA |
| Nitisinone – NITYR |
Cycle Pharmaceuticals Ltd. |
Medical (PDF – 358 KB) |
Clinical pharmacology (PDF – 4 MB) |
None |
PREA |
| Nitisinone – NITYR |
Cycle Pharmaceuticals Ltd. |
Medical (PDF – 358 KB) |
None |
None |
PREA |
Nivolumab – Opdivo |
Bristol-Myers Squibb Company |
DD (PDF – 188 KB)
Medical (PDF – 222 KB)
|
Clinical pharmacology (PDF – 202 KB)
Clinical pharmacology (PDF – 250 KB)
|
Noen |
PREA |
| Nivolumab – Opdivo |
Bristol-Myers Squibb Company |
Medical (PDF – 8 MB) |
None |
None |
BPCA |
| Nivolumab – Opdivo |
Bristol-Myers Squibb Company |
Medical (PDF – 11 MB) |
None |
None |
BPCA |
|
Nivolumab and relatlimab-rmbw – Opdualag
|
Bristol-Myers Squibb Company |
Medical (PDF – 29 MB) |
None |
None |
PREA |
| Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules – Taytulla |
Warner Chilcott Company, LLC |
Medical (PDF -1MB) |
Clinical pharmacology (PDF -3.2MB) |
Statistical (PDF – 469 KB) |
PREA |
| Obiltoxaximab – Anthim |
Elusys Theraputics, Inc. |
Medical (PDF -18 MB)
Addendum (PDF – 249 KB)
|
Clinical pharmacology (PDF -12MB)
Addendum (PDF -126 KB)
|
Statistical (PDF – 9 MB) |
PREA |
| Ocriplasmin- Jetrea |
ThromboGenics, Inc. |
Medical (PDF – 817 KB) |
Clinical pharmacology (PDF – 117KB) |
Statistical (PDF – 760 KB) |
PREA |
| Olanzapine and fluoxetine hydrochloride – Symbyax |
Eli Lilly and Company |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF -1.2MB)
Addendum (PDF – 132KB)
|
Statistical (PDF – 953 KB) |
PREA |
| Olopatadine – Pazeo |
Alcon Research LTD |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF -340KB) |
Statistical (PDF – 4 KB) |
BOTH |
| Olopatadine hydrochloride and mometasone furoate – Ryaltris |
Glenmark Specialty SA |
Medical (PDF – 6 MB)
CDTL (PDF – 6 MB)
|
None |
None |
PREA |
| Omalizumab – Xolair |
Genentech |
Medical (PDF – 6 MB) |
Clinical pharmacology (PDF -1.3MB) |
Statistical (PDF – 2MB) |
PREA |
| Omalizumab – Xolair |
Genentech, Inc. and Novartis Pharmaceuticals Corp. |
Medical (PDF- 4 MB) |
Clinical pharmacology (PDF -1MB) |
Statistical (PDF – 1 MB) |
PREA |
|
Omalizumab – Xolair
|
Genentech, Inc. and Novartis Pharmaceuticals Corp. |
Medical (PDF – 5 MB) |
None |
None |
PREA |
| Omalizumab – Xolair |
Genentech, Inc. |
Medical (PDF – 8 MB) |
None |
None |
PREA |
| Omeprazole magnesium – Prilosec |
AstraZeneca Pharmaceuticals LP |
Medical (PDF – 908 KB) |
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
|
OnabotulinumtoxinA – Botox
|
Allergan, Inc. |
CDTL (PDF – 403 KB)
Medical (PDF – 1 MB)
|
None |
Statistical (PDF – 173 KB) |
PREA |
| OnabotulinumtoxinA – Botox |
Allergen, Inc |
Medical (PDF – 3 MB)
Medical (PDF – 1 MB)
|
None |
Statistical (PDF – 1 MB) |
PREA |
| OnabotulinumtoxinA – Botox |
Allergen, Inc |
Medical (PDF – 1 MB) |
None |
None |
PREA |
OnabotulinumtoxinA – Botox |
Allergan, Inc. |
Medical (PDF – 1 MB) |
None |
Statistical (PDF – 2 MB) |
PREA |
OnabotulinumtoxinA – Botox |
Allergan, Inc. |
Medical (PDF – 3 MB) |
None |
None |
PREA |
| Oxaprozin – Coxanto |
Solubiomix, Inc. |
Medical (PDF – 3 MB) |
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
| Oxcarbazepine – Oxtellar XR |
Supernus Pharmaceuticals, Inc. |
Medical (PDF – 5 MB) |
Clinical pharmacology (PDF – 7 MB) |
Statistical (PDF – 482 KB) |
PREA |
| Oxycodone hydrochloride – Oxycodone hydrochloride |
Genus Lifesciences, Inc. |
Medical (PDF – 2 MB)
DD Memo (PDF – 1 MB)
|
Clinical pharmacology (PDF – 688 KB) |
None |
PREA |
| Oxycodone hydrochloride – Oxycontin |
Purdue Pharma L.P. |
Medical (PDF – 17 MB) |
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF – 678 KB) |
BPCA |
| Oxymorphone – Opana |
|
Medical (PDF – 17 MB) |
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
| Ozenoxacin – Xepi |
Ferrer Internacional S.A. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF – 524 KB) |
PREA |
| Paclitaxel – Abraxane |
Abraxis BioScience, L.L.C., a wholly-owned subsidiary of Celgene Corporation |
Medical (PDF – 235 KB) |
None |
None |
BPCA |
| Palifermin – Kepivance |
Quintiles, Inc. |
Medical (PDF – 280 KB) |
Clinical pharmacology (PDF – 726 KB) |
None |
PREA |
| Palonosetron hydrochloride – Aloxi |
Helsinn Healthcare SA |
Medical (PDF – 15 MB)
Medical (PDF – 2 MB)
|
Clinical pharmacology (PDF -2 MB) |
Statistical (PDF – 771 KB) |
BOTH |
| Pancrelipase – Creon |
AbbVie Inc. |
Medical (PDF – 566 KB) |
None |
None |
PREA |
| Pancrelipase – Pancreaze |
Janssen Pharmaceuticals, Inc. |
Medical (PDF – 142 KB) |
None |
None |
PREA |
| Pancrelipase – Pertzye |
Digestive Care, Inc. |
Medical (PDF – 1 MB) |
None |
None |
PREA |
| Pancrelipase – Zenpep |
Aptalis Pharma Limited. |
Medical (PDF – 587 KB) |
None |
None |
PREA |
| Paricalcitol – Zemplar |
AbbVie Inc. |
Medical (PDF – 3 MB)
CDTL (PDF – 1 MB)
|
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF – 427 KB) |
PREA |
| Patiromer – Veltassa |
Vifor Pharma, Inc. |
Medical (PDF – 3 MB) |
None |
None |
PREA |
|
Pegfilgrastim-cbqv – UDENYCA
|
Coherus BioSciences, Inc
|
Medical (PDF – 184 KB)
Medical (PDF – 228 KB)
CDTL (PDF – 584 KB)
|
Clinical pharmacology (PDF – 968 KB) |
Statistical (PDF – 199 KB) |
PREA |
| Pegfilgrastim-fpgk – Stimufend |
Fresenius Kabi USA, LLC |
CDTL (PDF – 198 KB) |
None |
None |
PREA |
| Pegfilgrastim-bmez – Ziextenzo |
Sandoz Inc. |
CDTL (PDF – 348 KB) |
None |
None |
PREA |
| Peginterferon alfa-2a – Pegays |
Hoffmann-La Roche, Incorporated |
Medical (PDF – 799 KB) |
Clinical pharmacology (PDF – 667 KB) |
Statistical (PDF – 667 KB) |
PREA |
| Peramivir – Rapivab |
BioCryst Pharmaceuticals, Inc. |
Medical (PDF – 767 KB |
Clinical pharmacology (PDF -468 KB) |
Statistical (PDF – 767KB) |
PREA |
Peramivir – Rapivab |
BioCryst Pharmaceuticals, Inc. |
Medical (PDF – 1 MB |
Clinical pharmacology (PDF – 81 KB) |
None |
PREA |
| Perampanel – Fycompa |
Eisai, Inc. |
Medical (PDF – 5 MB) |
Clinical pharmacology (PDF -6MB) |
Statistical (PDF -1.2MB) |
PREA |
| Perampanel – Fycompa |
Eisai, Inc. |
Medical (PDF – 3 MB) Medical (PDF – 2 MB) |
Clinical pharmacology (PDF -4MB) |
Statistical (PDF -1.3MB) |
PREA |
| Perampanel – Fycompa |
Eisai Inc. |
Medical (PDF – 3 MB)
Medical MTL (PDF – 678 KB)
|
Clinical pharmacology (PDF -1.2MB) |
None |
PREA |
| Perampanel – Fycompa |
Eisai Inc. |
Medical (PDF – 79 KB) |
Clinical pharmacology (PDF – 86 KB) |
None |
PREA |
|
Perampanel – Fycompa
|
Eisai Inc.
|
CDTL (PDF – 452 KB)
Medical (PDF – 5 MB)
|
Clinical pharmacology (PDF – 2.5 MB) |
None |
PREA |
Perflutren lipid microsphere – DEFINITY and DEFINITY RT |
Lantheus Medical Imaging, Inc. |
Medical (PDF – 719 KB) |
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF – 858 KB) |
PREA |
|
Pentermine and topiramate – Qsymia
|
VIVUS LLC |
Medical (PDF – 9 MB) |
Clinical pharmacology (PDF – 587 KB) |
Statistical (PDF – 858 KB) |
PREA |
| Phentolamine mesylate – OraVerse |
Septodont Holding Sas |
Medical (PDF – 3 MB) |
None |
Statistical (PDF – 1 MB) |
PREA |
| Phenylephrine hydrochloride ophthalmic solution |
Paragon BioTeck, Inc. |
Medical (PDF – 1MB) |
Clinical pharmacology (PDF – 95 KB) |
Statistical (PDF -1 MB) |
PREA |
|
Phentolamine ophthalmic solution – Ryzumvi
|
Ocuphire Pharma, Inc. |
CDTL (PDF – 1 MB)
Medical (PDF – 1 MB)
|
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
| Phenylephrine and ketorolac – Omidria |
Omeros Corporation |
CDTL (PDF – 1 MB) Medical (PDF – 4 MB) |
None |
Statistical (PDF – 816 KB) |
BPCA |
| Piperacillin and tazobactam – Zosyn |
Wyeth Pharmaceuticals LLC |
Medical (PDF – 2 MB) |
None |
None |
PREA |
|
Pitavastatin – Livalo
|
Kowa Pharmaceuticals America, Inc. |
CDTL Review (PDF – 526 KB)
Medical (PDF – 2 MB)
|
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 240 KB) |
BPCA |
| Pomalidomide – POMALYST |
Celgene Corporation |
Medical (PDF – 15 KB) |
Clinical pharmacology (PDF – 1 MB) |
None |
BPCA |
| Posaconazole – Noxafil |
Merck Sharp & Dohme Corp. |
Medical (PDF – 3 MB) |
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF – 252KB) |
PREA |
| Posaconazole – Noxafil |
Merck |
Medical (PDF – 602 KB) |
Clinical pharmacology (PDF – 645 KB) |
None |
PREA |
| Posaconazole – Noxafil |
Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc. |
Medical (PDF – 8 MB) |
None |
None |
PREA |
| Potassium phosphate |
Fresenius Kabi USA, LLC |
Medical (PDF – 602 KB) |
None |
None |
PREA |
| Prasugrel – Effient |
Eli Lilly and Company |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 911 KB) |
Statistical (PDF -290 KB) |
BPCA |
| Pregabalin – Lyrica |
Pfizer |
Medical (PDF – 4 MB) |
Clinical pharmacology (PDF – 6 KB) |
Statistical (PDF – 825 KB) |
PREA |
| Pregabalin – Lyrica |
PF PRISM CV |
Medical and Statistical (PDF – 1 MB) |
Clinical pharmacology (PDF – 1.3 MB) |
Medical and Statistical (PDF – 1 MB) |
PREA |
| Pregabalin – Lyrica |
Pfizer |
CTDL Review (PDF – 1 MB)
Medical (PDF – 1 MB)
|
Clinical pharmacology(PDF -1 MB) |
Statistical (PDF – 2 MB) |
BOTH |
| Quetiapine fumarate – Seroquel and Seroquel XR |
AstraZeneca Pharmaceuticals LP |
CTDL Review (PDF – 1 MB)
Medical (PDF – 3 MB)
|
Clinical pharmacology (PDF – 2 MB)
Clinical pharmacology (PDF – 739 KB)
|
Statistical (PDF – 785 KB) |
PREA |
| Rabeprazole sodium – AcipHex Sprinkle |
Eisa Inc. |
Medical (PDF – 3 MB) |
Clinical pharmacology (PDF – 5 MB) |
Statistical (PDF 185 KB) |
BOTH |
|
Ramucirumab – Cyramza
|
Eli Lilly and Company |
Medical (PDF – 198 KB) |
Clinical pharmacology (PDF – 168 KB) |
None |
BPCA |
| Raltegravir – Isentress |
Merck Sharp Dohme Corp |
Medical (PDF – 1MB) |
Clinical pharmacology (PDF – 2 MB) |
None |
PREA |
| Raltegravir – Isentress |
Merck Sharp Dohme Corp |
CDTL Review (PDF – 5 MB) |
Clinical pharmacology (PDF – 5 MB) |
Statistical (PDF 874 KB) |
PREA |
| Raltegravir – Isentress |
Merck Sharp Dohme Corp |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 1 MB) |
None |
BOTH |
|
Ravulizumab-cwvz – Ultomiris
|
Alexion Pharmaceuticals, Inc. |
Medical (PDF – 5 MB) |
None |
None |
PREA |
| Remdesivir – Veklury |
Gilead Sciences, Inc. |
Medical (PDF – 1 MB)
Medical (PDF – 776 KB)
|
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 225 KB)
Statistical (PDF – 782 KB)
|
PREA |
Remdesivir – Veklury |
Gilead Sciences, Inc. |
CDTL (PDF – 3 MB) |
None |
None |
PREA |
Remdesivir – Veklury |
Gilead Sciences, Inc. |
CDTL (PDF – 3 MB) |
None |
None |
PREA |
| Remdesivir – Veklury |
Gilead Sciences, Inc. |
CDTL (PDF – 4 MB) |
None |
None |
BOTH |
| Reslizumab – Cinqair |
Teva Respiratory, LLC |
Medical (PDF – 5 MB) |
Clinical pharmacology (PDF – 9 MB) |
Statistical (PDF – 2 MB) |
PREA |
| Rifapentin – Priftin |
Sanofi US Services Inc. |
Medical (PDF – MB) |
Clinical pharmacology (PDF – 5 MB) |
Statistical (PDF – 3 MB) |
PREA |
| Rilpivirine – Edurant |
Janssen Products L.P. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF -138 KB) |
None |
PREA |
| Rilpivirine – Edurant |
Janssen Products L.P. |
Medical (PDF – 41 MB) |
Clinical pharmacology (PDF – 2 MB)
Clinical pharmacology (PDF – 235 KB)
|
|
PREA |
| Rilpivirine – Edurant |
Janssen Products, LP |
Medical (PDF – 9 MB) |
None |
None |
BPCA |
| Rivaroxaban – Xarelto |
Janssen Pharmaceuticals, Inc. |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 10 MB) |
Statistical (PDF – 797 KB) |
BOTH |
| Risperidone – Risperdal Consta |
Janssen Pharmaceuticals, Inc. |
DD Summary Review (PDF – 20 KB)
CTDL Review (PDF – 1MB)
Medical (PDF – 670KB)
Medical (PDF – 667 KB)
|
None |
Statistical (PDF – 237KB) |
PREA |
| Ritlecitinib – Litfulo |
Pfizer, Inc. |
Medical (PDF – 15 MB) |
None |
None |
PREA |
|
Rituximab-arrx – Riabni
|
Amgen, Inc. |
Medical (PDF – 7 MB) |
None |
None |
PREA |
| Rizatriptan – RizaFilm |
IntelGenx Corp. |
Medical (PDF – 352 KB)
Memo (PDF – 851 KB)
|
Clinical pharmacology (PDF – 220 KB) |
None |
PREA |
| Roflumilast – Zoryeve |
Arcutis Biotherapeutics, Inc. |
Medical (PDF – 6 MB) |
None |
None |
PREA |
|
Roflumilast – Zoryeve
|
Arcutis Biotherapeutics, Inc. |
Medical (PDF – 5 MB) |
Clinical pharmacology (PDF – 3 MB) |
None |
PREA |
| Roflumilast – Zoryeve |
Arcutis Biotherapeutics, Inc. |
Medical (PDF – 5 MB) |
None |
None |
PREA |
| Rosuvastatin – Ezallor Sprinkle |
Sun Pharmaceutical Industries Limited |
Medical (PDF – 27 KB) |
None |
None |
PREA |
| Rufinamide – Banzel |
Eisai Inc. |
Medical (PDF – 10 MB) |
Clinical pharmacology (PDF – 3MB) |
None |
BPCA |
| Ruxolitinib – Jakafi |
Incyte Corporation |
Medical (PDF – 685 KB) |
Clinical pharmacology (PDF – 533 KB) |
None |
BPCA |
| Ruxolitinib – Jakafi |
Incyte Corporation |
Medical (PDF – 685 KB) |
None |
None |
BPCA |
|
Ruxolitinib – Opzelura
|
Incyte Corporation |
Medical (PDF – 9 MB) |
None |
None |
PREA |
| Ruxolitinib – Opzelura |
Incyte Corporation |
Medical (PDF – 7 MB) |
None |
None |
PREA |
| Sacubitril-valsartan – Entresto |
Novartis Pharmaceuticals Corp. |
Medical (PDF – 685 KB) |
Clinical pharmacology (PDF – 533 KB) |
Statistical (PDF -1MB) |
BPCA |
| Sacubitril-valsartan – Entresto NEW |
Novartis Pharmaceuticals Corp. |
CDTL (PDF – 727 KB)
Medical (PDF – 9 MB)
|
Clinical pharmacology (PDF – 6 MB) |
None |
PREA |
| Sapropterin dihydrochloride – Kuvan |
BioMarin Pharmaceutical Inc. |
Medical (PDF – 4 MB) |
Clinical pharmacology (PDF -3 MB) |
None |
BPCA |
| Saquinavir mesylate – Invirase |
Hoffmann La-Roche, Inc.orporated c/o Genentech, Inc. |
Medical (PDF -1 MB) |
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF -1MB) |
BOTH |
|
Sarecycline – Seysara
|
Allergan, Inc. |
Medical (PDF -1 MB) |
None |
None |
PREA |
| Secnidazole – Solosec |
Lupin Pharmaceuticals, Inc. |
Medical (PDF 4 MB) |
None |
None |
PREA |
| Secnidazole – Solosec |
Lupin Pharmaceuticals, Inc. (A subsidiary of Lupin Inc.) |
Medical (PDF 2 MB) |
None |
None |
PREA |
|
Secukinuma – Cosentyx
|
Novartis Pharmaceuticals Corporation |
Medical (PDF – 6 MB) |
None |
None |
PREA |
| Selegiline – Emsam |
Somerset Pharmaceuticals |
Medical (PDF -1 MB)
Medical 2 (PDF -1 MB)
Medical Secondary 1 (PDF – 349 KB)
Medical Secondary 2 (PDF -188 KB)
|
None |
None |
PREA |
| Selenious Acid – Selenious Acid |
American Regent, Inc. |
Medical (PDF – 8 MB) |
None |
None |
PREA |
| Selenious Acid – Selenious Acid |
American Regent, Inc. |
Medical (PDF – 8 MB) |
None
|
None |
PREA |
| Segesterone acetate and ethinyl estradiol vaginal systems – Annovera |
The Population Council, Inc. |
Medical (PDF – 5 MB) |
None |
None |
PREA |
| Semaglutide – Wegovy |
Novo Nordisk Inc. |
Medical (PDF – 8 MB)
|
Clinical pharmacology (PDF – 16 MB) |
Statistical (PDF – 869 KB) |
PREA |
| Serdexmethylphenidate and dexmethylphenidate – Azstarys |
Commave Therapeutics |
Multidisciplinary (PDF – 7 MB) |
None |
None |
PREA |
| Sevelamer Carbonate – Renvela |
Genzyme/Sanofi |
Medical (PDF – 745 KB) |
Clinical pharmacology (PDF – 542 KB) |
Statistical (PDF – 541KB) |
PREA |
|
Sitagliptin – Januvia, Janumet & Janumet XR
|
Merck Sharp & Dohme Corp.: |
CDTL (PDF – 1 MB)
Medical (PDF – 4 MB)
|
Clinical pharmacology (PDF – 339 KB) |
Statistical (PDF – 623 KB) |
BOTH |
| Sildenafil – Revatio |
Pfizer, Inc. |
Medical (PDF – 6 MB) |
Clinical pharmacology (PDF -2MB) |
Statistical (PDF – 508 KB) |
BOTH |
| Sodium oxybate – Xyrem |
Jazz Pharmaceuticals |
Medical (PDF – 193 KB) |
Clinical pharmacology (PDF – 2MB) |
Statistical (PDF – 508 KB) |
BPCA |
| Sodium picosulfate, magnesium oxide, and anhydrous citric acid – Prepopik |
Ferring Pharmaceuticals Inc. |
Medical (PDF – 193 KB) |
None |
None |
PREA |
| Sodium sulfate, potassium sulfate, and magnesium sulfate – Suprep Bowel Prep Kit |
Sponsor: Braintree Laboratories, Inc. |
Medical (PDF – 193 KB) |
None |
None |
PREA |
|
Sodium picosulfate, magnesium oxide and anhydrous citric acid – Clenpiq
|
Ferring Pharmaceuticals Inc.
|
CDTL (PDF – 1 MB) |
None |
None |
PREA |
| Sofpironium – Sofdra |
Botanix SB Inc. |
Uniview (PDF – 4 MB)
Medical (PDF – 133 KB)
|
None |
None |
PREA |
| Spinosad – Natroba |
ParaPRO, LLC |
Medical (PDF – 854 KB) |
Clinical pharmacology (PDF -171KB) |
None |
PREA |
| Sofosbuvir – Sovaldi |
Gilead Sciences, Inc. |
Medical and CDTL (PDF – 345 KB) |
Clinical pharmacology (PDF – 511 KB) |
None |
PREA |
| Sofosbuvir – Sovaldi |
Gilead Sciences, Inc. |
Medical (PDF – 218 KB) |
None |
None |
PREA |
| Sofosbuvir and velpatasvir – Epclusa |
Gilead Sciences, Inc. |
Medical (PDF – 218 KB) |
Clinical pharmacology (PDF – 511 KB) |
None |
PREA |
| Sofosbuvir and velpatasvir – Epclusa |
Gilead Sciences, Inc. |
Medical (PDF – 287 KB) |
Clinical pharmacology (PDF – 4 MB) |
None |
BOTH |
| Solifenacin succinate – VESIcare |
Astellas Pharma Global Development, Inc. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 933KB) |
Statistical PDF – 960 KB) |
BOTH |
| Solifenacin succinate – VESIcare |
Astellas Pharma Global Development, Inc. |
Medical (PDF – 3 MB)
CDTL (PDF – 1 MB)
|
Clinical pharmacology (PDF -2MB) |
Statistical (PDF – 960 KB) |
BOTH |
| Spinosad – Natroba |
ParaPRO LLC |
Medical (PDF – 458 KB) |
None |
None |
PREA |
| Sulfur Hexafluoride Lipid-Type A Microspheres) for Injectable Suspension – Lumason |
Bracco Diagnostics Inc. |
Medical (PDF – 5 MB) |
Clinical pharmacology (PDF -2MB) |
Statistical (PDF -792KB) |
PREA |
| Sulfur Hexafluoride Lipid-Type A Microspheres – Lumason |
Bracco Diagnostics, Inc. |
Medical (PDF – 3MB)
CDTL (PDF – 1 MB)
|
Clinical pharmacology (PDF – 1MB) |
Statistical (PDF – 859 KB) |
PREA |
| Sulfur Hexafluoride Lipid-Type A Microspheres – Lumason |
Bracco Diagnostics, Inc. |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF -843 KB) |
PREA |
Sugammadex – Bridion |
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. |
Medical (PDF – 3 MB |
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF – 2 MB) |
PREA |
| Sumatriptan/Naproxen – Treximet |
Pernix Therapeutics |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF -843 KB)
Statistical Addendum (PDF -702 KB)
|
BOTH |
| Sunitinib malate – Sutent |
C.P. Pharmaceuticals International C.V. |
CDTL (PDF – 680 KB) |
None |
None |
BPCA |
| Tacrolimus – Astagraf XL |
Astellas Pharma US, Inc.
|
Medical (PDF – 749 KB) |
None |
None |
PREA |
| Tadalafil – Cialis |
Eli Lilly and Company |
Medical (PDF – 1 MB) |
Clinical pharmacology (PDF – 1 MB) |
None |
BPCA |
| Tapentadol – Nucynta |
Collegium Pharmaceutical, Inc. |
CDTL – DD (PDF – 9 MB) |
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF -700 KB) |
PREA |
| Tavaborole – Kerydin |
Anacor Pharmaceuticals, Inc. |
Multi-disciplinary review (PDF – 2.5 MB) |
None |
None |
BOTH |
| Tazarotene – Arazlo |
Bausch Health US, LLC |
Clinical (PDF – 1 MB) |
None |
None |
PREA |
| Tbo-filgrastim – Granix |
Sicor Biotech UAB c/o Teva Branded Pharmaceutical Products R&D |
CDTL (PDF – 176 KB)
Clinical (PDF – 196 KB)
|
Clinical pharmacology (PDF – 434 KB) |
None |
BOTH |
| Technetium 99m Tilmanocept – Lymphoseek |
Cardinal Health 414, LLC |
Multidisciplinary (PDF – 2 MB) |
None |
None |
PREA |
| Kit for the Preparation of Technetium Tc 99m Succimer Injection -NephroScan |
Theragnostics Inc |
Medical (PDF – 5 MB) |
None |
None |
PREA |
| Tedizolid phosphate – Sivextro |
Cubist Pharmaceuticals, LLC |
Medical (PDF – 9 MB) |
None |
None |
PREA |
| Teduglutide – GattexShire |
Shire-NPS Pharmaceuticals, Inc. |
Medical (PDF – 9 MB) |
None |
None |
PREA |
| Tenofovir alafenamide – Vemlidy |
Gilead Sciences, Inc |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 624 KB) |
PREA |
| Tenofovir disoproxil fumarate – Viread |
Gilead Sciences |
Medical (PDF – 2 MB) |
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF – 1 MB) |
PREA |
| Tenofovir disoproxil fumarate – Viread |
Gilead Sciences |
CDTL (PDF – 873 KB) |
Clinical pharmacology (PDF – 180 KB) |
Statistical (PDF – 149 KB) |
BOTH |
| Teplizumab-mzwv -Tzield |
Provention Bio, Inc. |
CDTL (PDF – 5 MB)
Medical (PDF – 284 KB)
|
Clinical pharmacology (PDF – 6 MB) |
None |
PREA |
| Teriflunomide – Aubagio |
Sanofi |
CTDL (PDF – 3 MB)
Clinical (PDF – 3 MB)
|
Clinical pharmacology (PDF – 2 MB) |
Statistical (PDF – 410KB) |
BOTH |
| Tetracaine hydrochloride – Steri-Unit |
Alcon Research, Ltd. |
DD Medical Summary (PDF – 2 MB)
Medical (PDF – 1 MB)
|
Clinical pharmacology (PDF – 158 KB) |
Statistical (PDF – 2 MB) |
PREA |
| Tetracaine HCl and Oxymetazoline HCl – Kovanaze |
St. Renatus, LLC |
Medical (PDF – 12 MB) |
Clinical pharmacology (PDF – 11 MB) |
Statistical (PDF – 2 MB) |
PREA |
|
Tezepelumab -Tezspir
|
AstraZeneca |
Medical (PDF – 10 MB) |
None |
None |
PREA |
Ticagrelor – Brilinta |
AstraZeneca Pharmaceuticals LP |
Medical (PDF – 10 MB) |
Clinical pharmacology (PDF – 1 MB) |
Statistical (PDF – 325 KB) |
BPCA |
Tilmanocept – Lymphoseek |
Cardinal Health 414, LLC |
Medical (PDF – 2 MB) |
None |
None |
PREA |
| Tiotropium bromide – Spiriva Respimat |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Medical (PDF -11.9MB)
Medical Addendum (PDF – 418 KB
|
Clinical pharmacology (PDF – 6 MB) |
Statistical (PDF – 1 MB)
Statistical Addendum (PDF – 327 KB)
|
PREA |
| Tiotropium bromide – Spiriva Respimat |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Medical (PDF – 5 MB) |
Clinical pharmacology (PDF – 2MB) |
Statistical (PDF – 432K B) |
BOTH |
| Tobramycin 300 mg/4mL inhalation solution – Bethkis |
Cornerstone Therapeutics |
Medical (PDF – 5 MB) |
Clinical pharmacology (PDF – 78 KB) |
Statistical (PDF – 687 KB) |
PREA |
|
Tocilizumab – Actemra
|
Genentech, Inc. |
Medical (PDF – 72 KB)
Medical (PDF – 109 KB)
|
Clinical pharmacology (PDF – 195 KB) |
None |
PREA |
|
Tocilizumab – Actemra
|
Genentech, Inc. |
Medical (PDF – 8 MB) |
None |
None |
BOTH |
| Tocilizumab-bavi – Tofidence |
Biogen MA Inc |
Medical (PDF – 5 MB) |
None |
None |
PREA |
| Tocilizumab-aazg -Tyenne |
Fresenius Kabi USA, LLC |
CDTL (PDF – 42K B)
Medical (PDF – 8 MB)
|
None |
None |
PREA
|
| Tofacitinib – Xeljanz |
Pfizer, Inc. |
Medical (PDF – 8 MB) |
None |
None |
PREA |
| Topiramate – Topamax |
Janssen Pharmaceuticals, Inc. |
Medical (PDF – 8 MB) |
None |
Statistical (PDF – 881 KB) |
PREA |
|
Topiramate – Eprontia
|
Azurity Pharmaceuticals, Inc. |
Medical (PDF – 669 KB) |
Clinical pharmacology (PDF – 565 KB) |
None |
PREA |
| Trabectedin – Yondelis |
Janssen Products, LP |
Medical (PDF – 3 MB) |
Clinical pharmacology (PDF – 683 KB) |
None |
BPCA |
| Trace elements injection 4 – Tralement |
American Regent, Inc. |
Medical (PDF – 2.5 MB) |
None |
None |
PREA |
| Trace elements injection 4 – Tralement |
American Regent, Inc. |
Medical (PDF – 321 KB) |
None |
None |
PREA |
| Tralokinumab-ldrm – Adbry |
LEO Pharma A/S c/o LEO Pharma Inc |
Unireview (PDF – 4MB)
Medical (PDF – 32 KB)
|
None |
None |
PREA |
| Trametinib – Mekinist |
Novartis Pharmaceuticals Corporation |
Medical (PDF – 18 MB) |
None |
None |
PREA |
| Trametinib – Mekinist |
Novartis Pharmaceuticals Corporation |
Medical (PDF – 800 KB) |
Clinical pharmacology (PDF – 616 KB) |
None |
BPCA |
| Tranexamic acid – Lysteda |
Ferring Pharmaceuticals, Inc. |
None |
Clinical pharmacology (PDF – 1 MB) |
None |
PREA |
| Tretinoin lotion – Altreno |
Dow Pharmaceutical Sciences, Inc. |
Medical (PDF – 3 MB) |
None |
None |
PREA |
| Tretinoin and benzoyl peroxide – Twyneo |
Sol-Gel Technologies Ltd. c/o B&H Consulting Services Inc. |
Medical (PDF – 2 MB) |
None |
None |
PREA |
| Trifarotene – Aklief |
Galderma Research and Development |
Medical (PDF – 3 MB) |
None |
None |
PREA |
| Trofinetide – Daybue |
Acadia Pharmaceuticals Inc |
Medical (PDF – 212 KB)
Medical (PDF – 6 MB)
|
Clinical pharmacology (PDF – 6 MB) |
Statistical (PDF – 2 MB)
Statistical Errata (PDF – 28 KB)
|
BPCA |
| Tropicamide and phenylephrine – MYDCOMBI |
Eyenovia, Inc. |
CDTL – DD (PDF – 6 MB) |
None |
Statistical (PDF – 2 MB) |
PREA |
| Upadacitinib – Rinvoq |
AbbVie Inc. |
Medical (PDF – 10 MB) |
None |
None |
PREA |
| Upadacitinib – Rinvoq and Rinvoq LQ |
AbbVie Inc. |
Medical (PDF – 4 MB) |
None |
None |
PREA |
| Ustekinumab – Stelara |
Janssen Biotech, Inc. |
Medical (PDF – 352 MB) |
Clinical pharmacology (PDF – 3 MB) |
None |
PREA |
| Ustekinumab – Stelara |
Janssen Biotech, Inc. |
Medical (PDF – 8 MB) |
None |
None |
PREA |
| Ustekinumab-aekn – Selarsdi |
Alvotech USA Inc. PharmaLex US Corporation |
CDTL (PDF – 123 KB)
Medical (PDF – 5 MB)
|
Clinical pharmacology (PDF – 9 KB) |
None |
PREA |
| Valganciclovir hydrochloride – Valcyte |
Roche Palo Alto LLC c/o Genentech, Inc.orporated |
Medical (PDF – 3 MB) |
Clinical pharmacology (PDF – 6 MB) |
None |
PREA |
|
Valsartan – Diovan
|
Novartis Pharmaceuticals Corporation |
Medical (PDF – 2 MB) |
None |
None |
PREA |
|
Varenicline – Chantix
|
PF Prism C V |
None |
Clinical pharmacology (PDF – 3 MB) |
None |
BOTH |
| Vilazodone hydrochloride – Viibryd |
Allergan Sales, LLC |
Medical (PDF – 3 MB) |
None |
None |
BOTH |
|
Vortioxetine – Trintellix
|
Takeda Pharmaceuticals, USA, Inc. |
Medical (PDF – 3 MB) |
None |
None |
BOTH |
| Vortioxetine – Trintellix |
Takeda Pharmaceuticals, USA, Inc. |
Medical (PDF – 3 MB) |
None |
None |
BOTH |
| Ustekinumab – Stelara |
Janssen Biotech Inc. |
CDTL (PDF – 593 KB)
Medical (PDF – 5 MB)
|
Clinical pharmacology (PDF – 3 MB) |
Statistical (PDF – 275 KB) |
PREA |
| Vigabatrin – Sabril |
Lundbeck LLC. |
Medical (PDF – 4MB) |
Clinical pharmacology (PDF – 2.3MB) |
Statistical (PDF – 698KB) |
BOTH |
Viloxazine extended release capsules – Qelbree |
Supernus Pharmaceuticals, Inc. |
Medical (PDF – 13 KB)
Medical (PDF – 13 MB)
|
None |
None |
PREA |
| Viloxazine extended-release capsules – Qelbree |
Supernus Pharmaceuticals, Inc. |
Medical (PDF – 2 MB) |
None |
None |
PREA |
| Voriconazole – Vend |
PF PRISM C.V. |
Medical (PDF – 2 MB)
Medical PDF – 200 KB)
|
Clinical Pharmacology (PDF – 1 MB) |
Statistical (PDF – 200 KB) |
PREA |
| Xenon Xe 129 hyperpolarized – XENOVIEW |
Polarean Inc. |
Medical PDF – 200 KB) |
None |
None |
PREA |
| Zinc sulfate – None |
American Regent, Inc. |
Medical (PDF – 4 MB) |
None |
None |
PREA |
Ziprasidone – Geodon |
Viatris Specialty LLC |
Medical (PDF – 2 MB) |
None |
None |
PREA |
| Zolmitriptan – Zomig |
AstraZeneca Pharmaceuticals LP |
Medical (PDF – 5 MB) |
None |
Statistical (PDF – 3 MB) |
PREA |
Source